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OBJECTIVES: The research activity focused on two research projects. 
In the first project, we investigated the effects of high local insulin 
levels on beta cell turnover in a model of endogenous hyperinsulinism. 
In the second project, we investigated the presence and quantity of 
amyloid deposits and their role on beta cell death in type 2 diabetes and 
diabetes secondary to pancreatic diseases.
BACKGROUND: 
Insulin therapy has been suggested to preserve beta-cell mass in 
patients with diabetes through the mechanisms of beta-cell rest as well as 
direct effects on beta-cell proliferation. However, data about the effects of 
hyperinsulinism on beta-cell mass and turnover in humans are sparse. 
Amyloid  aggregates  have  been suggested  to  be  involved in  the 
pathogenesis of type 2 diabetes, causing beta cell death. Data present in 
literature make IAPP role in type 2 diabetes controversial.
PATIENTS AND METHODS: 
First research project: pancreatic tissue specimens from 5 patients 
with pancreatic insulinomas and 10 non diabetic control  subjects  were 
examined. Pancreatic sections were stained for insulin, Ki67 (replication) 
and  TUNEL (apoptosis),  and  quantitative  morphometric  analyses  were 
performed. 
Second research project: pancreatic tissues from 7 patients with 
type  2  diabetes,  10  patients  with  diabetes  secondary  to  chronic 
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pancreatitis or pancreatic carcinoma and 11 non diabetic control subjects 
were  examined.  Pancreatic  sections  were  stained  for  insulin,  TUNEL 
(apoptosis) and Thioflavin S (amyloid) and morphometric analysis were 
performed.
RESULTS: 
First research project: fractional beta-cell area was 1.11%±0.67% 
in the tumor-free pancreatic tissue of the insulinoma patients and 0.78%
±0.26% in the control group (p=0.19). There also were no differences in 
islet  size  (p=0.62)  or  beta-cell  nuclear  diameter  (p=0.20).  Beta-cell 
replication  and  apoptosis  were  infrequently  detected,  without  any 
measurable  differences  between  the  groups.  There  were  also  no 
differences  in  percentage  of  duct  cells  expressing  insulin  (p=0.47),  a 
surrogate marker for islet neogenesis. 
Second research  project:  fractional  beta  cell  area  was 0.33% ± 
0.07% in  the  pancreatic  tissue of  patients  with  diabetes  secondary  to 
pancreatic diseases, 0.57% ± 0.09% in patients with type 2 diabetes and 
0.76% ± 0.13% in the control group (p=0.021). There were no differences 
in beta cell apoptosis (p=0.10) and extent of islet amyloid (p=0.13) or islet 
amyloid area (p=0.24) 
CONCLUSIONS: 
Beta-cell  area  and  turnover  are  not  significantly  altered  in  the 
proximity of  intra-pancreatic insulinomas. Future in vivo studies,  ideally 
employing larger  animal  models,  are warranted to  further  evaluate the 
impact of exogenous insulin on beta-cell turnover. 
A significant difference in beta cell area but no differences in beta 
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cell apoptosis and amyloid deposition were found between type 2 diabetic 
patients,  patients  with  diabetes  secondary  to  chronic  pancreatitis  or 
pancreatic carcinoma and control  subjects.  Amyloid deposition is not a 
cause  of  beta  cell  death  in  type  2  diabetes.  Future  larger  studies, 
involving also appropriate animal models and sophisticated techniques, 
could be useful to better understand the aggregation mechanisms of IAPP 
and its role in beta cell death.
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1. INTRODUCTION
1.1 Pancreatic beta cells
Beta cells are the most diffuse endocrine cells in the Langerhans 
islets, roundly-oval shaped cell aggregates, highly vascularized, spread in 
the pancreas. Islet cells are organized in cords among a network of blood 
vessels, in which blood flows from the core to the islet's periphery (1). In 
an adult, total Langerhans islets weight is about 1-1,5 g and the size of 
every islet can range from less than 100 cells or 50  µm in diameter to 
more than 5.000 cells or 500 µm in diameter (1). 
The pancreatic islets consist of four endocrine cell types:
-beta cells: with a multifaceted shape and clustered all around the blood 
vessels mainly in the core of the islet; they represent approximately 60-
80% of the endocrine cells and secrete insulin.
-alfa cells: with a cylindrical shape and dispersed throughout the islet; they 
are  smaller  than  beta  cells,  represent  approximately  10-15%  of  the 
endocrine cells and secrete glucagon.
-delta  cells:  dispersed  in  the  islet  like  alfa  cells;  they  represent 
approximately 5-10% of the endocrine cells and secrete somatostatin. 
-pp  cells:  localized  in  the  periphery  of  the  islet;  they  represent 




 Figure 1: Histology of human pancreas. Histological sections of human pancreas 
are stained for islet hormones. Micrographs of four different human islets show 
the intermingling of β and non-β cells. (A–D) Magnification X40; β cells, green; α 
cells, red; δ cells, blue.  (Brissova M et al. J Histochem Cytochem 2005; 53, 9:  
1087-1097).
In a mean size islet (150 µm in diameter) there are 1.000-1.500 beta cells 
and each of them has more than 10.000 granules of insulin (2).  
The granules have a diameter of about 0,25-0,40 µm and can be of 
two different types: those mature, uniformly distributed in the cytoplasm 
with a rectangular crystalline electrondense midpoint and those immature, 
more clear  and close to  the Golgi  apparatus forming a roundish mass 
sorrounded  by  a  clathrin  membrane.  Pro-insulin  is  synthesized  in  the 
rough  endoplasmic  reticulum  (RER)  and  packaged  into  immature 
secretory granules in the trans-Golgi network, a tubular-reticular structure 
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associated  with  the  trans  face  of  the  Golgi,  together  with  proinsulin 
conversion enzymes. When granules mature, the clathrin coat is lost and 
the intragranular environment becomes acid and proinsulin is converted to 
insulin and C-peptide. The insulin is stored into the granules as crystals 
with Zn2+ (3).  
In addition to the genes for insulin (insulin-1 and insulin-2), there 
are  other  two  markers  characteristic  of  beta  cells:  IAPP (islet  amyloid 
polipeptide)  gene,  encoding  a  peptidic  hormone secreted together  with 
insulin and GLUT-2 gene, encoding the glucose transporter of beta cell. 
Glucose is the most important stimulus for insulin secretion; other 
stimuli  are  represented  by  nutrients,  hormones,  neurotransmitters  and 
drugs (4, 5).  
After entry into the beta cell through the uniporter GLUT 2, glucose 
is phosphorylated by the glucokinase enzyme and goes into the glycolysis 
reaction. Pyruvate, the end product of glycolysis, enters the mitochondria 
and goes into the citric acid cycle and, through the following steps in the 
mitochondrial respiratory chain, there is production of ATP. The increase in 
the cellular ATP/ADP ratio induces the  closure of the ATP-dependent  K+ 
channels on the cell membrane, then, leading to membrane depolarization 
and activation of voltage-dependent Ca2+
 
channels that makes cytosolic 
[Ca2+] increase (6-8). Elevated cytosolic [Ca2+] leads to the stimulation of 
insulin exocytosis  (9, 10). 
But the Ca2+ signal alone is not sufficient for a sustained secretion 
because under clamped cytosolic [Ca2+], glucose can still stimulate insulin 
secretion  (11),  suggesting  the  existance  of  mitochondrial  messengers, 
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different from ATP, involved in this mechanism (12).  These messengers 
can  be  glutamate,  malonyl  CoA,  long-chain  acyl  CoAs  (LC-CoA),  and 
NADPH. 
Glutamate is formed from  α-ketoglutarate,  an intermediate in the 
citric  acid  cycle,  by mithocondrial  enzyme glutamate dehydrogenase.  It 
has been shown that glutamate directly stimulates insulin exocytosis  in 
permeabilized  cells,  under  conditions  of  fixed  cytosolic  [Ca2+] in  a 
mechanism,  prabably,  involving  the  reduction  of  granular  membrane 
potential  or  the  Ca2+  uptake into the granules (13,  14) or the granules 
swelling and their fusion with the plasma membrane (15).
Long-chain acyl CoAs (LC-acyl CoAs) are involved in the insulin 
secretion  through the link between glucose stimulated  insulin  secretion 
(GSIS) and lipid synthesis (16, 17). After exposure of pancreatic beta cells 
to  glucose,  malonyl  CoA content  rises,  leading  to  an inhibition  of  fatty 
acids oxidation and increase in lipid synthesis. Elevated levels of LC-acyl 
CoAs,  derived  from  glucose  metabolism  as  well  as  endogenous  or 
exogenous  lipids,  can stimulate  insulin  secretion  through  an increased 
fusion  of  secretory  granules  with  the  beta  cell  plasma membrane in  a 
mechanism  involving  the  acylation  or  binding  to  specific  proteins  like 
SNARE or VAMP, important for insulin exocytosis (18). 
NADPH can be generated in several reactions in the cell and also 
from  pyruvate  in  the  pyruvate-malate  shuttle  system  across  the 
mitochondrial  inner  membrane.  Increased  intracellular  NADPH/NADP+ 
ratio  extends the  inactivation  of  voltage dependent  K+  current  by  ATP-
dependent  K+  channels  on  the  cell  membrane,  then,  inhibiting  the 
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repolarisation of beta cell (19). 
In addition to these mitochondrial molecules, there are also other 
substances affecting insulin secretion. 
The sulfonylureas bind to  a  specific  receptor  SUR1 on the ATP-
dependent  K+  channels  and,  directly,  cause  their  closure  with 
depolarization  of  cell  membrane  and  insulin  release  from  beta  cell 
granules through an increase of intracellular [Ca2+]  (8). 
Aminoacid arginine enters the beta cell and, because of its negative 
charge,  causes  cell  membrane  depolarization  and,  then,  activation  of 
voltage-dependent  Ca2+
 
channels  with  the  consequent  increase  in 
cytosolic [Ca2+] and insulin secretion (20).





















The insulin secretion has a biphasic nature: the first phase is rapid, 
transient and lasts about 5-10 minutes while the second one is slow and 
sustained. The rate of insulin secretion (expressed as percentage of islet 
insulin content released per minute) is 0,14%/min in the first phase while it 
is 0,05%/min in the second phase (21). These rates correspond to about 
18  granules  released  per  min  per  beta  cell  in  the  first  phase  and  6 
granules per min per beta cell in the second phase. Then, the total number 
of granules secreting insulin in the first phase is about 100 per beta cell, 
meaning  that  only  10%  of  the  total  granule  number  in  a  beta  cell  is 
responsable for the first insulin release. These granules are called readily 
releasable pool (RRP) and are associated to the plasma membrane. In 
contrast, the second phase is dependent from granules that form the, so 
called,  reserved pool  that  release insulin  after  being transported to the 
plasma membrane (22). 
The insulin  exocytosis is  highly regulated by a fusion machinery 
composed of SNARE proteins. This machinery is formed by two groups of 
SNARE proteins: those associated with plasma membrane, syntaxin1 and 
SNAP25, and that associated with secretory granules membrane, VAMP2. 
VAMP2 binds to syntaxin1 and SNAP25, forming a complex that forces the 
two plasma and secretory granule membranes together and with the Ca2+ 
channels on the beta cell surface. When Ca2+ channels open, intracellular 
ion content increases, activating a  Ca2+-sensitive protein in the SNARE 
complex,  called  synaptotagmin,  that  leads  to  the  fusion  of  the  two 
membranes (23, 24). The  intragranular pH becomes less acid triggering 
the dissolution of crystal insulin and its release from the beta cell. 
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Then, insulin secretion is a finely regulated mechanism in order to 
keep plasmatic glucose concentrations constant  either  in  fast  time and 
after meals. Anyway, an adequate insulin secretion depends not only on a 
functional beta cell  but also on a sufficient number of cells or beta cell 
mass that can assure a physiological amount of plasmatic insulin.
Figure 3: Insulin exocytosis involving SNARE and VAMP proteins. (Rorsman P 







1.1.1 Beta cell mass
Beta cell mass is regulated by four mechanisms: beta cell size, beta 
cell replication, beta cell neogenesis or differentiation of precursor cells in 
pancreatic duct epithelium and beta cell  apoptosis. While the first three 
processes preserve and expand the beta cell mass, the last one provokes 
its reduction.
The contribution of each of these mechanisms to the manteinance 
of beta cell  mass differs in a species specific way (25). For example, it 
seems that beta cell replication rather than neogenesis plays a crucial role 
to produce new endocrine cells in young adult mice (26, 27), instead, both 
the processes appear to be important to increase the beta cell mass in 
humans (28, 29). It is plausible to think that the difference observed in beta 
cell  replication and neogenesis can be ascribed to a different  telomere 
lenght  regulation  and  biology  in  these  two  species.  The  telomere 
shortening limits the replicative capacity of cells during aging in humans, 
while  this  mechanism  normally  lacks  and  is  not  related  to  replicative 
senescence  in  mice  (29,  30).  This  phenomenon  can  hide  the  real 
contribution of beta cell neogenesis in forming new beta cells in mice.
Anyway,  beta  cell  mass  is  a  dynamic  entity  that  can change  at 
different stages of life and under different stimuli.
During prenatal life, pancreatic beta cells are detected in humans 
from gestational  week 9 arising  from possible  precursor  cells  in  ductal 
epithelium and beta cell replication occurs from that time during all stages 
of prenatal development. Beta cell apoptosis is also detectable in all these 
ages, suggesting an high level of beta cell turnover (31). 
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Figure  4:  Images  show  the  dorsal  pancreatic  evaginations  from  gut  in  two 
foetuses at week 8 (a and b) and at week 9 (c and d) p.c. Images were acquired 
at 100x (a and c) and at 400x magnification (b and d). Section were stained for 
glucagon (brown) (a and b) and for insulin (brown) and CD31 (red) (c and d). Red 
arrows point to endocrine cells next  to exocrine ducts.  (Meier  JJ et  al.  Eur J 
Endocrinol. 2010; 162, 3: 559-68).
Based on rodent studies, it is supposed that beta cell turnover still takes 
place  just  after  birth  with  high  peaks  of  beta  cell  replication  and 
neogenesis and a small increase in beta cell apoptosis (32). 
During childhood and adult life, beta cell replication declines (33) as 
a result of different expression and activity of specific cell cycle regulators. 
Infact, cell cycle inhibitors, as the tumor suppressor protein p16 and the 
cyclin dependent kinase inhibitor p27, are much higher expressed in the 
beta cells of human adult rather than in prenatal beta cells (34).  Besides 
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beta cell replication, also beta cell neogenesis and apoptosis decline with 
aging,  though  apoptosis  can  slightly  increase  in  old  years.  Then,  by 
balancing of these beta cell turnover events, beta cell mass reaches a kind 
of physiological level that is maintained during all adult life.
Changes from this level can be noted in some physiological and 
pathological conditions as pregnancy, obesity and type 2 diabetes.
During pregnancy there are complex endocrine and metabolic long 
term modifications in the mother body in order to respond to an increased 
metabolic  load,  then,  to  provide nutrients  to  the  fetus  and prepare  the 
maternal  organism  to  childbirth  and  lactation.  In  particular,  the  main 
adaptive  changes  in  response  to  a  growing  need  for  insulin  are:  an 
increased glucose-stimulated insulin secretion with a lowered threshold for 
glucose-stimulated insulin secretion, an increased beta cell activity with an 
increased  insulin  synthesis  and  an  increased  glucose  metabolism. 
Besides  these  changes, it  is  evident  an  expansion  of  beta  cell  mass 
mainly due to the effects of maternal hormones, prolactin and placental 
lactogen, on the islets (35) that stimulate not only insulin secretion but also 
beta cell replication as seen in rat,  mouse and human islets in vitro. In 
particular,  activation  of  the  prolactin  receptor  stimulates  the 
phosphorylation  and  nuclear  accumulation  of  signal  transducer  and 
activator of transcription 5 (STAT5), which, then, represses menin through 
Bcl6 expression, allowing the beta cells to proliferate (36).
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Figure 5: Regulation of beta cell proliferation via the prolactin receptor signalling 
(Kargar C. et al. Diabetes, obesity and metabolism 2008 Nov; 10, Suppl 4: 43-
53.).
After  partum,  the  beta  cell  mass  reaches  again  a  physiological  level 
through a reduction of beta cell  replication and an increase of beta cell 
apoptosis (37, 38).  
Obesity is a multifactorial  disease characterized by an excessive 
adipose  tissue  mass.  It  is  often  associated  with  insulin  resistance,  a 
reduced ability of insulin to promote glucose uptake by peripheral tissues. 
Obesity  and  insulin  resistance  bring  to  an  increased  metabolic  load 
causing a beta cell mass growth (28, 39), sustained by an high rate of beta 
cell  replication,  neogenesis  and  a  rise  in  cell  volume  as  seen  in 
experiments with obese rats and in human autopsy studies (28, 40). In this 
obese condition, when the beta cells loose the ability to compensate for 
the insulin resistance, diabetes comes.
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Type 2 diabetes is a disease in which, contrary to what happen in 
pregnancy and obesity, the beta cell mass appears to be reduced.
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1.2 Beta cell mass in type 2 diabetes
Diabetes is a disease characterized by multiple metabolic changes 
caused by various etiopathogenetic mechanisms. Type 2 diabetes is the 
most  common  form  of  diabetes  and  is  caused  by  disorders  of  insulin 
biological action and deficit of insulin secretion, due to not well understood 
mechanisms. In this condition the beta cell  mass shows both functional 
and quantitative changes.
From a functional  point  of  view,  beta cells  gradually  reduce and 
loose the first  phase of insulin secretion with deficit  also in the second 
release  phase  as  diabetes  progresses.  Glucose-stimulated  insulin 
secretion  is  reduced  but  the  hormon  secretion  stimulated  by  other 
substances,  as  arginine,  is  slightly  affected  showing  the  presence  of 
alterations in the glucose signaling pathway inside the beta cell (41). 
Figure 6: Early phase of insulin secretion from control and type 2 diabetic islets 
during perifusion experiments. Cell  preparations are perifused with 3.3 mmol/l 
glucose solution for 30 min, and then with either 16.7 mmol/l glucose, 3.3 mmol/l 
glucose  plus  20  mmol/l  arginine,  or  3.3  mmol/l  glucose  plus  100  μmol/l 
glibenclamide. Type 2 diabetic islets (b) do not show increase in insulin secretion 
during 16.7  mmol/l glucose compared with control islets (a).  *P < 0.05 of 16.7 
mmol/l  glucose  vs.  the  other  experimental  conditions. (Del  Guerra  S.  et  al.  
Diabetes 2005; 54, 3:727-35).    
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Another defect is the increased ratio proinsulin/insulin, that results 
from an altered conversion of  proinsulin in insulin and C-peptide in the 
mature beta cell granules (42). 
From a quantitative point of view, the beta cell mass is reduced in 
type 2 diabetes both in humans and animal models and the magnitude of 
decrease correlates with the disease duration (43). The reduction of the 
beta cell  mass in humans depends on reduction of  islets  quantity (43), 
reduction  of  beta  cells  in  the  islets  for  an  increased  apoptosis,  quite 
evident in larger islets (43, 44), and reduction of beta cell mature granules 
(45).
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1.2.1 Beta cell mass in animal models of type 2 diabetes
Many animal models of type 2 diabetes show a decrease in the 
beta cell mass.
Goto-Kakizaki  (GK)  rat  is  one  of  these;  a  non-obese  Wistar 
substrain that, spontaneusly, develop type 2 diabetes mellitus early in life. 
GK  rat  model  has  the  same  defects  related  to  functional  and 
morphological  characteristics  of  beta  cells  that  are  also  present  in  the 
islets of type 2 diabetic patients,  then,  proving to be a useful model to 
understand the basis of diabetes in humans.  The GK rats show fasting 
hyperglycemia  soon  after  the  birth,  glucose  intolerance  and  impaired 
glucose-induced insulin secretion due to an impaired function of beta cells, 
further worsed by chronic exposure to hyperglycemia (46), and a reduction 
of the beta cell mass to 50% of control Wistar rats. A reduced beta cell 
mass, due to problems during development, is mainly considered to be the 
primary defect leading to hyperglycemia and overt diabetes in this model. 
Infact,  treatment  with  GLP-1  and  its  long-acting  analog  exendin-4 
improves the glycemic control and severity of type 2 diabetes through a 
stimulation of beta cell replication and neogenesis (47). 
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                       Wistar (▪)     GK (□)     GK/GLP-1 (▴)     GK/Ex-4 (▵) 
Figure 7. Basal plasma glucose and insulin levels of Wistar (▪), GK (□),GK/GLP-
1 (▴) and GK/Ex-4 (▵) from ages 7 days to 2 months. The increase in basal 
plasma glucose seen in GK group is blunted in the GK/GLP-1 and GK/Ex-4 rats 
(a).  Tolerance  to  glucose  measured  as  ΔG  in  the  four  groups.  Tolerance  to 
glucose is improved in the GK/GLP-1 and GK/Ex-4 rats even if it does not reach 
the normal value in Wistar group (b). §§§P < 0.001, §P < 0.05 vs. Wistar rats; *P 
< 0.05 vs. untreated GK rats. (Tourrel C et al. Diabetes 2002; 51, 5: 1443-52).
Another model of experimental type 2 diabetes is represented by 
the Zucker diabetic fatty rats that lack the leptin receptor, and, then, inherit 




they loose the glycemic control and hyperglycemia comes followed by a 
reduction of plasma insulin levels. During this period, the beta cell mass 
decreases till  to  be almost  50% less  compared to  control  non diabetic 
obese rats, showing that anomalies related to beta cell mass expansion 
contribute to hyperglycemia and are associated to a decrease of beta cell 
replication (40) and beta cell apoptosis (48). 
Like Zucker diabetic fatty rats, db/db mice have a mutation in the 
leptin receptor and, spontaneously, become obese and hyperinsulinaemic. 
After 1 month from the birth, they develop hyperlipidemia, hyperglycemia, 
glucose intolerance and show a reduced beta cell  mass and an altered 
beta  cell  function  associated  with  anomalies  in  beta  cell  differentiation 
(49). The expression of genes involved in the maturation and maintenance 
of cellular differentiation, like PDX-1, Beta2/NeuroD, Nkx6.1 and Pax6, is 
reduced  as  well  as  the  expression  of  genes  involved  in  the  beta  cell 
glucose metabolism like the glucose transporter of beta cells, GLUT2, and 
the enzyme glucokinase important  for  the glucose phosphorylation and 
metabolism.  Also  genes,  encoding  ion  channels  taking  part  in  the 
stimulation of insulin secretion, like kir6.2, a subunit of the ATP-sensitive 
K+  channel, and SERCA2b and SERCA3, a sarco/endoplasmic reticulum 
Ca2+-ATPase  pump show  an  altered  expression  pattern  (50).  The 
reduction of beta cell mass in db/db mice can result also from incresead 
apoptotic events as proved by the activation, in the islets isolated from 
these mice, of X-box binding protein 1 (Xbp1) mRNA, a transcription factor 
partecipating in the unfolded protein response (UPR), a stress-signaling 
pathway  active  during  the  accumulation  of  unfolded  proteins  in  the 
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endoplasmic reticulum (ER). Hyperglycaemia and high circulating levels of 
lipids in db/db mice can cause ER stress, eventually, culminating to beta 
cells apoptosis when UPR fails (51).
While the association between an altered functional beta cell mass 
and the onset or progression of diabetes is clear in these type 2 diabetes 
animal models, it is less evident or absent in others.
Psammomys obesus is a diurnal gerbil living in North African and 
Eastern  Mediterranean  semi-desert  regions.  In  its  habitat,  with  a  low-
calorie diet,  it  is neither obese nor hyperglycemic but few days of high 
calorie diet are enough to make this animal obese and diabetic. After 1 
day of high calorie food, the hyperglycemia is associated with a reduction 
of 80-90% in pancreatic insulin reserve without changes in beta cell mass. 
On  the  following  day,  beta  cell  mass  decreases  of  40-50%  to, 
spontaneously, return at the prediabetic level thanks to an increase in beta 
cell  proliferation  and  neogenesis.  But  the  pancreatic  insulin  content 
remains low, meaning. probably, that the new formed beta cells are not 
functionally  mature and not  able  to  secrete enough insulin  to  stop the 
hyperglycemia. A poor calorie diet reverses the diabetes status bringing to 
an increase in pancreatic insulin reserve without any changes in beta cell 
mass, showing that not beta cell mass but insulin content and secretory 
capacity determines the progression of diabetes in this animal model (52) . 
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Figure  8: Blood  glucose  (a),  pancreatic  insulin  content  (b)  in  diabetic  prone 
Psammomys obesus animals analysed at the ages of 11, 12 and 14 weeks on 
the HE (high calorie) diet and 14 weeks of HE diet followed by 2 days of LE (light 
calorie) diet. *P < 0.05 relative to animals in the 12 W and 14 W groups. (Kaiser 
N et al. Diabetes 2005; 54, 2: 137-44).
Figure  9:  Beta  cell  mass  in  diabetic  prone  Psammomys  obesus  animals 
analysed at the ages of 11, 12 and 14 weeks on the HE diet and 14 weeks of HE 




Also partial pancreatectomy animal models contribute to investigate 
the  role  that  beta  cell  mass  has  in  the  onset  of  hyperglycemia  and 
diabetes.  Experiments  in  rats  show  that  40%  pancreatectomy  has  no 
effect on plasma glucose levels or insulin secretion in vivo and in vitro and 
the regrowth of beta cells, as showed by measurements of beta cell mass 
19 days after  surgery,  is  responsible  for  the maintenance of  endocrine 
pancreatic normal function (53).  But, while changes in plasma glycemic 
control are not associated to 40% reduction of beta cell mass, they are in 
the case of subtotal 90% pancreatectomy.  8-10 weeks after this kind of 
surgery, the remnant pancreas is analyzed showing an increase of both 
beta cell  mass and not beta cell  mass as well as pancreatic content of 
insulin, glucagon and somatostatin. Anyway, these improvements in beta 
cell  mass  are  not  associated  with  a  parallel  improvement  in  the  islet 
function as the beta cell response to glucose results impaired (54).  
Another  model  of  experimentally  induced  type  2  diabetes  is  the 
streptozotocin (STZ) treated rats.  STZ is a naturally occurring chemical 
toxic  to  the  beta  cells  and  a  single  injection  of  low-dose  STZ  causes 
moderate diabetes in adult rats. Two months after the injection, the beta 
cell mass is restored but insulin secretory defects are still present and 48-h 
glucose infusion to stimulate beta cell growth does not have effects on cell 
function despite a great increase in beta cell mass (55).
In  conclusion,  the  data  from  these  animal  models  show  as  the 
reduction  of  beta  cell  mass  is  associated  to  a  decrease  in  beta  cell 
function. It is the case of spontaneous animal models of type 2 diabetes: 
GK  rat,  ZDF  rat  and  db/db  mouse.  Instead,  the  correlations  between 
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changes in beta cell mass and beta cell function lack in other conditions. It 
is  the  case  of  experimental  animal  models  of  type  2  diabetes:  partial 
pancreatectomy, psammomys obesus and STZ injection where variations 
in the beta cell mass are not associated to changes in the beta cell activity. 
The difference between these two kinds of type 2 animal models can lay in 
their different metabolic environment. It is possible, infact, that states of 
prolonged hyperglycemia and hyperlipidemia,  such as those present  in 
pancreatectomized rats, STZ injected rats and psammomys obesus, can 
interfere with the growth of fully functional beta cells and normal control of 
plasma glucose levels.
The observations coming from these models, anyway, are useful to 
understand the mechanisms and the role of beta cell mass in the human 
type 2 diabetes despite the genetic differences of these species.
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1.2.2 Beta cell mass in human type 2 diabetes
The difficulties in studying the beta cell mass in humans are related 
to the lack of instruments for in vivo measurements. Then, most of the 
data come not  only  from animal  models but  also from human autopsy 
studies.
In this sense, Rahier et al. are the first to perform their experiments 
in cadaveric donors. While at beginning, the scientists are not able to find 
any differences in the beta cell  mass between type 2 diabetic and non 
diabetic  control  subjects  (56),  after  following experiments,  they show a 
reduction in beta cell mass of 41% and 38% in lean and obese diabetic 
patients,  respectively,  compared  with  controls.  Also  pancreatic  insulin 
concentration results to be decreased in diabetics and while the beta cell 
mass is not correlated with age at the diagnosis, it decreases with duration 
of  clinical  diabetes.  Infact,  it  is  24%  and  54%  lower  than  controls  in 
subjects  with <5 and >15 years  of  diabetes,  respectively,  showing that 
diabetes itself contributes to beta cell dysfunction (57).
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 Figure  10:  Inverse  correlation  between  beta  cell  mass  and  the  duration  of 
diabetes (a).  Beta cell  mass in diabetic patients subdivided in 3 categories of 
duration  of  clinical  diabetes  (b).  (Rahier  J  et  al.  Diabetes,  Obesity  and 
Metabolism 2008; 10, 4: 32-42).
Also Butler  et  al.  suggests  that  a decrease in beta cell  mass is 
involved in an impaired insulin secretion. Obese subjects with impaired 
fasting glucose (IFG) and type 2 diabetes have a 40% and 63% reduction 
in relative beta cell volume compared with non diabetic obese cases while 
lean patients with type 2 diabetes show a 41% decrease compared with 
non diabetic lean cases. Beta cell replication and neogenesis rates are not 
different  among groups unlike apoptosis  frequency that  is  increased in 
type 2 diabetes cases compared with non diabetic controls, underlying that 
cellular death is the main mechanism responsible for the reduction of beta 
cells (28). The Langerhans islets isolated from type 2 diabetic cadaveric 
donors  are  smaller  than  islets  isolated  from  controls  with  a  reduced 
proportion of beta cells and an increased proportion of alfa cells. In some 
cases, beta cells are not present and alfa cells are more diffuse throughout 
the islet while the proportion of other endocrine cells is unchanged (43). 
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Figure 11:  Fasting plasma glucose (a) and beta cell volume (b) in obese (non 
diabetic, IFG and diabetic) and lean (non diabetic and diabetic) cases.  *P<0.05 
compared with non diabetic obese subjects. ϯP<0.05  compared with non diabetic 
lean subjects. (Butler AE et al. Diabetes 2003; 52, 1: 102-10).
Figure 12: Frequency of beta cell apoptosis in obese (non diabetic and diabetic) 
and lean (non diabetic and diabetic) cases. *P<0.05 compared with non diabetic 




Islets  from  diabetic  patients  are  not  only  morfologically  and 
quantitatively  altered but  show also functional  anomalies.  They secrete 
less total  insulin and exhibit  a more elevated threshold for  the glucose 
stimulated  insulin  response  in  in  vitro  islet  perifusion  assay  and  when 
transplanted to immunodeficient diabetic mice, they are not able to restore 
euglycemia contrary to normal control islets (43).
If on the one hand the studies on cadaveric donors are useful for 
quantitative  analysis  of  pancreatic  tissue,  on  the  other  hand  they  can 
present some limits: postmortem autolysis in the pancreas (58) and lack of 
clinical data of subjects with unrecognized diabetes (59).  Keeping in mind 
those  possible  problems, Yoon  et  al.  perform their  experiments  in  live 
people with and without type 2 diabetes undergone to pancreatectomy for 
removal of benign or malignant pancreatic tumors. As in studies involving 
cadaveric donors, these diabetic patients have a reduction of relative beta 
cell volume and beta cell mass and an increase of relative alfa cell volume 
and  alfa  cell  mass  together  with  a  high  insular  alfa/beta  cell  ratio 
compared with control patients (44).
 The importance to have a proper quantity of functional beta cells to 
keep  plasma  glucose  levels  within  normal  values  range  in  humans  is 
evident in the curvilinear relationship existing between beta cell mass and 
fasting  glucose  concentration  whereby  at  values  upper  than  a  certain 
pancreatic  endocrine  mass (1.1  ± 0.1%),  great  changes correspond to 
small  changes in plasma glucose levels, whereas, at values lower than 
that  threshold  endocrine  mass,  small  changes  correspond  to  great 
changes in plasma glucose levels (60).
 30
Figure 13: Relationship between percentage of beta cell volume in pancreas and 
plasma glucose in obese humans without insulin or oral antidiabetic treatment. 
(Ritzel RA. et al. Diabetes care 2006 March; 29, 3: 717-718.).
As  the  reduction  of  beta  cell  mass  contributes  to  the  loss  of 
glycemic control  and development of  hyperglycemia in  type 2 diabetes 
(28, 60),  strategies to promote beta cell  regeneration and lower plasma 
glucose levels can reverse or prevent the onset of the disease (60).
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1.3 Beta cells regeneration as a cure for type 2 diabetes
The idea of enhancing beta cell regeneration as a potential future 
treatment approach for patients with diabetes has been prompted by the 
significant deficit in pancreatic beta cell mass in patients with type 1 and 
type 2 diabetes and the beta cell ability to regenerate (61, 62).  We have 
seen  that  beta  cell  mass  is  a  dinamic  entity  that  increases  in  some 
conditions,  as  pregnancy  and  obesity  (63),  through  replication  of 
preexisting beta cells and transdifferentiation of endocrine progenitor cells 
residing inside the ductal epithelium (28, 35). Then, appropriate stimuli can 
induce the formation of new beta cells.  Several experimental studies have 
demonstrated some potential for beta cell  regeneration in rats and mice 
even if in dependence of age. Young mice increase beta cell replication 
and, then, beta cell mass, maintaining normoglycemia, in response to high 
fat diet, a single dose of STZ and after short-term treatment with exendin-
4, glucagon-like peptide 1 (GLP-1) agonist in contrast to old mice (64, 65). 
Among various pharmacological agents able to enhance new beta 
cell formation in vitro and in animal models, the gut hormones glucagon 
like  peptide  1  (GLP-1),  gastric  inhibitory  polypeptide  (GIP)  and  gastrin 
have recently gained widespread attention.
GLP-1 is encoded in the proglucagon gene and results from a post-
translational  cleavage  of  the  product  of  this  gene  by  the  prohormone 
convertase PC1/3. It  is a hormone mainly produced in enteroendocrine L 
cells of the gut and secreted into the blood stream when food containing 
fat, protein hydrolysate and/or glucose enters the duodenum. It has been 
seen  that  GLP-1  stimulates  the  glucose-induced  insulin  secretion  in 
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subjects with an impaired glucose tolerance and type 2 diabetes (66) and 
has an insulinotropic effect as it enhances insulin gene transcription, that 
in rats is mediated by the activation of cAMP response element (CRE) of 
the insulin 1 gene promoter (RIP1) (67), and insulin biosynthesis (68). It, 
also, regulates the expression of genes encoding proteins implicated in 
the  glucose  transport,  like  GLUT2,  and  metabolism,  like  glucokinase, 
through the PI 3-kinase/PDX-1 transduction signalling pathway in INS-1 
cells (69) and enhances beta cell  proliferation via transactivation of the 
epidermal growth factor receptor (EGFR). The hormone binds its receptor 
GLP-1R on the surface of beta cell membrane and activates the tyrosine 
kinase  c-Src  that  is  responsible  for  the  proteolytic  processing  of 
membrane-anchored beta cellulin (BTC) or another EGF-like ligands, that 
binds to EGFR causing the activation of PI 3-kinase pathway (70).
Like  GLP-1,  also  glucose-dependent  insulinotropic  polypeptide 
(GIP) stimulates insulin secretion through the amplification of exocytosis, 
as shown in mouse pancreatic beta cells, and preserves beta cell mass, 
inhibiting cellular apoptosis. GIP activates the PI-3k/PkB pathway leading 
to phosphorylation of Foxo1 and down regulation of bax, a pro-apoptotic 
member of the Bcl-2 family (71).  As a result of the insulinotropic effects, 
the incretin hormones, GLP-1 and GIP, are used in type 2 diabetes therapy 
with two approaches: extending the half-lives inhibiting their degradative 
enzyme, dipeptidyl peptidase IV (72), and producing long acting incretin 
analogs (73).
Regarding gastrin, it  has been shown that the hormone  promotes 
beta  cell  replication  in  patients  with  pancreatic  gastrinomas  (76) and 
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induces, in combination with the epidermal growth factor (EGF), islet beta 
cell  neogenesis  in  rodents  (75) and  adult  human  islets  (74).  Then,  in 
addition  to  GLP-1  and  GIP  therapies,  complementary  approaches  to 
regeneration of beta cell mass in type 2 diabetes can be represented by 
the combination of agents, such as EGF and gastrin.  
Figure 14: Fractional beta cell area (a) and frequency of beta cell replication (b) 
in  tumour-adjacent  and  tumour-distant  pancreatic  sections  from  patients  with 
gastrinomas  and  control  subjects.  *P<0.001  compared  with  control  subjects. 
(Meier JJ et al. Diabetologia 2006; 49, 11: 2689-96).
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1.3.1 Effects of insulin on beta cells turnover
Insulin belongs to a family of correlated proteins called insulin like 
growth factors, IGF, and is involved in the energy metabolism regulation. 
Its primary function is to lower the plasma glucose levels, promoting the 
glucose uptake into the muscles and adipose tissue by glucose transporter 
4  (GLUT4)  and  into  the  liver  through  an  increase  of  glucose 
phosphorylation  and  glucose  utilization  for  the  glycogen  synthesis  and 
metabolism.  Then ,  insulin  increases  the  synthesis  of  proteins  and 
glycogen into the muscles and triglycerides into the adipose tissue. Beside 
this function, insulin has also some beneficial effects on islet cell turnover: 
i t can stimulate the beta cell  replication through PI  3-kinase and Raf-1 
kinase  pathways  activation  in  mouse  islets  (78)  and prevents  the  cell 
apoptosis  induced  by  serum withdrawal in  primary  human  and  mouse 
islets  in  vitro.  This  last  effect  is  associated  with  an  increase  of  Pdx1 
translocation to the nucleus and is absent in islets 50% deficient in the 
transcription factor, showing that it is an important target of insulin (77). In 
addition, treatment with insulin in patients soon after the diagnosis of type 
2 diabetes has beneficial effects more than treatment with sulphonylurea 
agent. Infact, It has been shown that, after 2 years of therapy,  glucagon-
stimulated  C-peptide  response and  fasting  insulin  levels  are  more 
increased  and  HbA1c  levels  are  better  in  patients  treated  with  insulin 
versus the glibenclamide group (79).  This shows that insulin improves the 
beta cell function and, then, the glycemic control. Similar results can also 
be seen in a chinese study involving newly diagnosed type 2 diabetes 
people in which  patients  treated with  an early  intensive insulin  therapy 
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obtain glycemic control in less time compared to patients treated with oral 
hypoglicemic agents. After normoglycemia is achieved and maintained for 
2 weeks in both groups, the drug therapy is suspended and the patients 
undergo  only  a  diet  and  physical  exercise.  After  1  year  follow  up  the 
remission rate results to be higher in the insulin group than in the oral 
agent  group,  as  well  as  the  beta  cell  function  estimated  by  the 
homeostasis model assessment (HOMA) (80).
Figure 15: HbA1c levels during the study (a) *P < 0.01 year 0 vs. 1, §P < 0.005 
year 0 vs. 2, #P < 0.01 year 1 vs. 2. Incremental or decremental values of fasting 
levels  of  insulin  versus  baseline  (b).  *P=0.02  glibenclamide  vs.  insulin.  ▪, 




1.4  ISLET  AMYLOID  POLYPEPTIDE  (IAPP):  General  
characteristics
As  mentioned  above,  the  Langerhans  islets  of  type  2  diabetes 
patients have morphological features related not only to changes in beta 
and alfa cells quantity but also to amyloid deposition and exocrine fibrosis. 
Amyloid is a specific protein aggregation in which molecules are in 
beta sheet  conformation and bound to  each other  mainly  by hydrogen 
bonds.  This  state  of  aggregation  creates  thin  fibrils  that  appear  as 
unbranching structures of 5-10 nm in diameter and indeterminate lenght at 
electron  microscopy  (81). The  fibrillogenic  peptide  is  the  Islet  Amyloid 
Polypeptide (IAPP), normally produced in the beta cell and stored in the 
secretory  granules  and cosecreted  with  insulin  in  response to  different 
stimuli. 
IAPP  is  a  37  aminoacids  peptide  derived  from  a  precursor, 
preproIAPP,  a  89  aminoacids  peptide encoded  by  a  gene  on  the 
chromosome  12  (82).  PreproIAPP  contains  a  signal  peptide  that  is 
removed in the endoplasmic reticulum (ER); then, proIAPP and proinsulin 
are cleaved by two endoproteases, the prohormone convertase 2 (PC2) 
and  the  prohormone  convertase  1/3  (PC1/3)  in  the  late  Golgi  and 
secretory granules. 
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Figure 16:  The aminoacid sequence of human proIAPP (a) and the aminoacid 
sequence of human proinsulin (b) with the cleavage sites for PC2 and PC1/3. 
(Westermark P et al. Physiol Rev 2011; 91, 3: 795-826).
IAPP is  a  fibrill-prone protein  and is protected from aggregation in the 
granules,  where  it's  highly  concentrated,  by  the  interaction  with  other 
molecules or ions, some of which can be the insulin, that strongly inhibits 
IAPP fibrils formation in vitro, pH and calcium concentration (83). Then, it 
is possible that changes in the secretory vesicles environment can induce 
the initial aggregation. IAPP is a hormone and exerts its activity binding to 
receptors, some of which have been identified in the brain (84) and renal 
cortex of rats (85).  Its functions are not fully understood although some 
physiological effects on Langerhans islets and central nervous system are 
clear.  In the first case, IAPP is involved in the regulation of insulin and 
glucagon  secretion:  the  basal  glucose  stimulated  insulin  secretion  is 
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enhanced when IAPP is at low concentrations, while it is inhibited when 
the hormone is at high concentrations (86). Although, IAPP inhibits also 
the glucagon release in hypoglycemic conditions or when stimulated by 
different secretagogues, like L-arginine, in isolated rat islets (86), the effect 
is not seen in all experiments, making IAPP role in this mechanism a bit 
controversial (87). In the second case, it has been shown that IAPP slows 
the  gastric  emptying  (90)  and  reduces  the  food  intake  in  rats  when 
administered either chronically (88) and at low doses (89) and in humans 
only when administered at low concentrations (91). Other effects of IAPP 
include vasodilatation (92), regulation of renal filtration (93) and calcium 
homeostasis (94). 
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1.4.1  IAPP  amyloidogenicity  and  type  2  diabetes  in  animal 
models
In the past, the role of IAPP in the pathogenesis of type 2 diabetes 
has not been extensively examined because of the lack of amyloidosis 
naturally  occurring  in  the  Langerhans  islets  of  laboratory  rodents.  The 
aminoacid  sequence  omology  of  IAPP  is  high,  about  80%,  between 
different mammalian species; in particular, -NH2 and -COOH terminal parts 
are conserved through the evolution, probably, because of their important 
biological activity.  Anyway,  only humans, non human primates and cats 
express a form of IAPP able to form amyloid fibrils that, instead, lacks in 
rodents.  In  vitro  experiments show that  peptides corrisponding to  IAPP 
aminoacid region 20-29 of human and cat species form amyloid like fibrils, 
while  the  corresponding  IAPP  segment  from  rodent  species  is  inert. 
Aminoacid substitutions have proved that the sequence at positions 25-29 
of human IAPP is highly amyloidogenic and the proline residue, a beta-
sheet breaker, present  at  position 28 in the molecule of many rodents, 
inhibits  the fibrils  formation  (95).  Then,  the protein  primary  structure is 
fundamental to determine the correct protein folding that, anyway, is also 
influenced by other  factors like pH, temperature and ion concentration. 
Keeping  in  mind  these  differences  in  IAPP structure  between  species, 
most  informations  related  to  islet  amyloidosis  associated  with  type  2 
diabetes come from experiments with domestic cats, monkeys, as well as 
transgenic rodents for human IAPP. 
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Figure 17:  The aminoacid sequence of proIAPP of some mammalian species. 
IAPP is strongly conserved but shows variation in the 20-29 region of IAPP. This 
corresponds  to  residues  31-40  of  proIAPP,  evident  in  the  red  box.  Proline 
residues 36 and 39 are essential for aggregation inhibition. (Westermark P et al.  
Physiological reviews 2011; 91, 3: 795-826).
Some studies performed in monkeys show that  amyloid deposits 
are present not only in the islets of diabetic animals, with an occupation of 
37-81%  of  the  insular  area,  but  also  in  normoglycemic  and 
hyperinsulinemic  monkeys,  where  amyloid  occupies  0.03%-45% of  the 
islet  space,  suggesting  that  fibril  aggregates  are  formed  prior  to the 
development of overt diabetes, possibly being a factor in the destruction of 
beta cells (96). Amyloid is more prevalent in aging monkeys and increases 
with severity of diabetes mellitus and its quantity correlates significantly 
with serum glucose, tryglicerides and insulin (97).  
In  diabetic  cats  the islet  amyloid  is  associated  with  a  significant 
decrease  in  alfa  and  beta  cell  volume  fractions  but  the  volume  of 
endocrine cells in normoglycemic glucose-intolerant cats is not different 
from controls, showing that the reduction in beta cell mass is not the only 
factor leading to diabetes and the replacement of beta cells with amyloid is 
not the cause of the disease although it can contribute to the progression 
of diabetes (98, 99). 
Further experiments come from baboons, in which islet amyloidosis 
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severity, meant as increase in the percentage of insular area occupied, 
correlates with fasting plasma glucose, HbA1c, glucagon values and beta 
cell  function parameters and furthermore with a decreased relative beta 
cell and increased relative alfa cell volumes. These results point out that 
probably the Langerhans islet dysfunction, a fundamental aspect of type 2 
diabetes,  depends  on  beta  cell  death,  alfa  cell  proliferation  and  islet 
amyloidosis (100) that, then, can be not only a result of the pathology but 
possibly also a causative factor.
Other aspects of  this complex relation between amyloid deposits 
and  type  2  diabetes  come  up  from  studies  in  transgenic  rodents 
expressing  human  IAPP gene,  mainly,  under  control  of  the  rat  insulin 
promoter  (101).  Some  of  these  mice  develop  diabetes  mellitus 
spontaneously (102) or under a diet high in fat  (103) or induction of insulin 
insensitivity (104).
In addition to amyloid deposits in the islets of animals with type 2 
diabetes,  there are also small  intra- and extracellular  amorphous IAPP 
aggregates  visible  prior  to  the  onset  of  the  disease  and  that  can  be 
important in affecting the beta cell survival (102).
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1.4.2 IAPP amyloidosis and type 2 diabetes in humans  
Islet  amyloidosis  is  described  for  the  first  time  by  Opie  that 
observes  scattered  groups  of  irregular,  rounded,  globular  masses  of 
hyaline material located immediately outside the capillary walls and larger 
deposits replacing the cells and occupying most of the insular area (105). 
Those  aggregates  have  been  found  to  be  comprised  of  a  major 
component,  protein  IAPP, and minor components,  apolipoprotein E,  the 
heparan sulfate proteoglycan perlecan and serum amyloid P component 
(SAP) (109-111). 
Since then, the amyloid deposits have been discovered in the islets 
of type 2 diabetic subjects at post-mortem with a percentage of patients 
varied from almost 100% to 40% or less (28, 106-108) and a main spread 
in the pancreas corpus, body, tail and anterior part of the head, but not in 
the caput, the 'pancreatic polypeptide rich' part of the head, underlining 
that  amyloid  occurs  only  in  the  islets  containing  beta  cells  (106).  The 
extent of islet amyloid deposition in diabetic patients is really variable; the 
number  of  islets  affected  is  very heterogeneous ranging  from < 1% to 
80%, as well as the amount of amyloid per islet ranging from <0.5% to up 
to 80% (106, 112-114). The frequency and intensity of islet amyloidosis is 
also  related  to  the  age  of  patients  (107,  108),  being  uncommon in 
individuals younger than 40 years and found in about 10% of the diabetics 
between 50 and 60 years of age and in over 50% of the diabetics over 70 
years (115).
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Figure 18: Islet amyloid deposits labelled with thioflavin S in 2 subjects with type 
2 diabetes. a) Islet from a 86 years old subject treated with oral agents. A mean 
of 3% islet area was occupied by amyloid in this subject b) Islet from a 76 years 
old subject treated with oral hypoglycemic drugs. A mean of 20% islet area was 
occupied by amyloid in this patient. (Clark A et al. Diabetologia 2004; 47, 2: 157-
169).
Islet  amyloid  is present  also in  non diabetic subjects  but  is  much less 
common  than  in  diabetics,  affecting  fewer  islets  with  a  less  extent,  in 
relation  to  age  of  patients  (108,  112,  114). The  presence  of  amyloid 
deposits in some subjects without type 2 diabetes and not in all  type 2 
diabetes patients makes the role of amyloid deposition in the onset and 
progression  of  this  kind  of  disease  quite  complex  in  humans.  Several 
studies have reported that islet  amyloidosis  is associated with reduced 
islet  volume  and  beta  cell  area  in  diabetics (106,  116) and  a  clear 
connection exists between the stage of type 2 diabetes and the extent of 
islet amyloid (117), suggesting that the role amyloid seems to have in the 
disease is related to beta cell dysfunction and death. 
Based on the  fact  that  amyloid  fibrils  of  Aβ protein  are  toxic  to 
neurons in Alzheimer's disease, different studies have been performed to 
evaluate if also amyloid fibrils of IAPP have the same toxic effects on the 
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cells.  It  has  been  shown  that  IAPP fibrils  provoke  beta  cell  apoptosis 
through a direct contact with the beta cell surface in rat and adult human 
islet cells (118) while small IAPP aggregates, called oligomers, trigger beta 
cell  death  through  the  formation  of  abnormal  vesicle-like  membrane 
structures that destabilize the cellular ionic homeostasis (119). They insert 
into  the  cell  membrane and produce these ion  channel-like  structures, 
mainly as trimers or octamers (122), in a mechanism dependent on lipid 
membrane composition, ion strenght and membrane potential (120, 121). 
IAPP oligomers and their cytotoxic properties have been studied in vitro 
mostly  using  high  resolution  microscopy  techniques,  like  time-lapse 
atomic-force microscopy, but, lately they have been observed also in vivo, 
in  transgenic  mice,  where  they  form intracellularly  within  the  secretory 
pathway and appear to disrupt the membranes of endoplasmic reticulum, 
Golgi, secretory granules and mitochondria (123). One study has reported 
that  there  is also  an  extensive  oligomer  deposition  in  islets  of  human 
pancreatic  tissue  where  apoptotic  beta  cells  are  more  diffuse  (114). 
Despite these results, the role of amyloid oligomers in the pathogenesis of 
type 2 diabetes is still controversial because of the lack of methods able to 
clearly detect IAPP oligomers in vivo. Infact, the antibody anti oligomers, 
A11,  used  in  the  experiments  with  human  and  mouse  pancreases, 
appears to bind, besides amyloidogenic species, also other natively folded 
proteins,  such as  heat  shock  proteins  (124)  and  alfa-synuclein  protein 
(125), proving to be less specific.  Furthermore, most post-mortem and in 
vitro studies have shown the presence of amyloid fibrils in type 2 diabetes 
patients (28, 106-108) in a strict contact with apoptotic beta cells (118), 
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suggesting their implication in membrane damage through the interaction 
with specific sensitive calcium channels on the cell surface, involved in the 
cell  survival  (126).  In  addition, others  studies  have  shown how  the 
inhibition of amyloid fibrils reduces the apoptosis of beta cells in culture 
(127, 128). Then, the role of IAPP aggregates in the pathogenesis of type 
2 diabetes is still  debatable as it  is not clear if  IAPP aggregates are a 
cause or consequence of beta cell  dysfunction or death and if they are 
cause,  which  structures,  fibrils  or  oligomers,  are  really  cytotoxic.  The 
development  of  methods  able  to  detect  in  a  specific  way  the  different 
forms  of  human  IAPP and  more  in  vivo  studies  could  elucidate  their 
mechanisms  of  action  in  type  2  diabetes  and  eventually  lead  to 
pharmacological  treatment  to  prevent  or  stop  the  decline  of  beta  cell 
function.
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2. AIM OF THE STUDY
The research activity we carried on is related to 2 research projects 
focusing  on  the  beta  cell  turnover  and  morphological  alterations  of 
Langerhans islets in a  condition of high insulin secretion and a reduced 
insulin  secretion  because of  faulty  beta  cells  or  because of  pancreatic 
diseases.
Then, the aim of the first project was to evaluate the effects of high 
local insulin levels on beta cell turnover in vivo, in a model of endogenous 
hyperinsulinism. Then, we examined the tumor-adjacent tissue of patients 
with intra-pancreatic insulinomas and pancreatic tissue of control subjects 
to evaluate possible differences in:
-Beta cell area              Fractional beta cell area, islet size and nuclear 
diameter of beta cells
-Beta cell turnover                Replication, apoptosis and neogenesis of beta 
cells
The  aim  of  the  second  project,  that  is  still  in  progress,  was  to 
examine the presence and quantity of amyloid deposits and their role on 
beta cell death in type 2 diabetes and diabetes secondary to pancreatic 
diseases. Then, we examined the pancreatic tissue of patients with type 2 
diabetes,  patients  with diabetes secondary to  pancreatitis  or  pancreatic 
carcinoma and control subjects to evaluate possible differences in:    
-Beta cell area                  Fractional beta cell area
-Beta cell death               Beta cell apoptosis
-Amyloid                 Extent of islet amyloid, Islet amyloid area
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3. MATERIALS AND METHODS (I)
3.1 Pancreatic tissue samples
3.1.1 Cases
Human pancreatic tissue was obtained at surgery from 5 patients, 
who underwent surgery for the removal of insulinomas (Table 1 and 2). 
The diagnosis of insulinoma was made on the basis of clinical symptoms 
(i.e. repeated fasting hypoglycaemia, resolution of symptoms by glucose 
administration, etc.), as well as prolonged fasting tests. In all cases, the 
clinical  diagnosis  was confirmed by a trained pathologist  based on the 
detection  of  insulin-positive  pancreatic  tumors.  Tumor-free  tissue  was 
available from all cases. 
3.1.2 Control subjects   
10 control subjects of similar age and BMI were chosen as controls 
(Table 1). All  control  patients had undergone pancreatic surgery for the 
removal of  intra or extra pancreatic tumours not influencing the beta cell 
mass and function:  benign pancreatic adenomas (n = 8), tumors of the 
choledochus  (n  =  1),  and  an  intraperitoneal  metastasis  from  breast 
carcinoma  (n  =  1).  In  all  tissue  samples,  significant  alterations  of  the 
overall  pancreatic  integrity  were  excluded  by  careful  histological 
examination. None of the control subjects had a history of diabetes, but 
fasting glucose concentrations were in the diabetic range in four of these 
patients. 
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Table 1. Tumour characteristics of cases.








Table 2. Characteristics of cases and control subjects.
Control subjects Cases
SEX (F+M) 8+2 3+2
AGE (years) 60.3 ± 21.3 54.0 ± 22.3
BMI (  kg/m²) 24.5 ± 3.2 24.6 ± 3.1
FASTING BLOOD 
GLUCOSE (  mg/dl) 
117.8 ± 28.49 86.8 ± 25.97
HbA1c (%) 5.56 ± 0.45 4.9 ± 0.54
Data are means ± SD.
3.2 Fluorescence and immunohistochemical tissue staining
Pancreatic  tissue  was  fixed  in  formaldehyde  and  embedded  in 
paraffin. Sequential 5 µm sections were stained as follows:
3.2.1  FRACTIONAL  BETA  CELL  AREA,  ISLET  SIZE,  BETA  CELL 
NUCLEAR DIAMETER AND BETA CELL NEOGENESIS
 To  assess  fractional  beta-cell  area,  islet  size,  the  percentage of 
insulin-positive duct cells, and the nuclear diameter of beta-cells, all tissue 
sections  were  immunohistochemically  stained  for  insulin  and  DNA as 
follows:  After  heating  at  37°C  over  night  or  at  58°C  for  30  minutes, 
pancreatic  tissue  sections  were  deparaffinised  in  two  subsequent  10-
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minute  xylene-incubations  and  subsequently  hydrated  through  graded 
alcohol-series  (100%,  95%,  70%,  water).  To  block  endogeneous 
peroxidase-activity,  70%  alcohol  contained  3%  hydrogen  peroxide. 
Antigen-retrieval  was  performed  in  DakoCytomation  Target  Retrieval 
Solution pH 9 (Dako, Glostrup, Denmark Code S 2367) by heating for 20 
minutes.  After  cooling of  the samples to  room temperature  and a brief 
rinse in distilled water, sections were subsequently blocked for unspecific 
protein binding with TBS containing 3% BSA and 0,2% Triton X100 for 10 
minutes and for endogeneous biotin by use of the Dako Cytomation Biotin 
Blocking  System  (Dako,  Code  X0590).  Then,  a  guinea-pig-derived 
antiserum against pig insulin was applied for 1 hour at a dilution of 1:400 
(Dako,  Glostrup,  Denmark  Code  A0564).  Subsequently,  insulin  was 
stained  red  by  the  use  of  the  Dako-LSAB  Real  Detection  System 
(Glostrup,  Denmark,  Code  K5005)  according  to  the  manufacturer`s 
recommendations with 5-minute-washes in TBS between the incubations. 
For  a  blue  nuclear  counterstaining,  specimens  were  incubated  in 
hematoxylin  (Dako,  Glostrup,  Denmark,  Code  S3301)  for  5  minutes 
followed  by  a  5-minute-incubation  in  tap  water.  Finally,  samples  went 
through a series of ascending alcohol concentrations (70%, 96%, 100%) 
and  were  mounted  with  Entellan  (Merck,  Darmstadt,  Germany,  Code 
1.07961.0/00). Under omission of the primary antibody, no staining could 
be observed.
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3.2.2   BETA CELL REPLICATION 
 Ki67-expression was visualised by the HRP-catalysed generation of 
a brown chromogen using the Dako-Envision Dual Link System (Glostrup, 
Denmark Code K4065) according to the instructions of the manufacturer. 
Insulin  was  stained  red  by  the  use  of  the  Dako-LSAB Real  Detection 
System (Glostrup,  Denmark,  Code  K5005).  After  heating  at  37°C over 
night  or  at  58°C  for  30  minutes,  pancreatic  tissue  sections  were 
deparaffinised in two subsequent 10-minute xylene-incubations and then 
hydrated  through  graded  alcohol-series  (100%,  95%,  70%,  water).  To 
block  endogeneous  peroxidase-activity,  70%  alcohol  contained  3% 
hydrogen peroxide. Antigen-retrieval  was performed in DakoCytomation 
Target Retrieval Solution pH 9 (Dako, Glostrup, Denmark Code S 2367) by 
heating for 20 minutes. After cooling of the samples to room temperature 
and a brief rinse in distilled water, sections were subsequently blocked for 
unspecific protein binding with TBS containing 3% BSA and 0,2% Triton 
X100  for  10  minutes  and  for  endogeneous  biotin  by  use  of  the  Dako 
Cytomation Biotin Blocking System (Dako, Code X0590). Then, the tissues 
were incubated in mouse primary antibody against  human Ki67 (Dako, 
Glostrup,  Denmark  Code  M7240  1:50)  for  1  hour.  Subsequently,  the 
antigen was stained brown by the use of the Dako-Envision-Kit  (Dako, 
Glostrup,  Denmark,  Code  K4065)  according  to  the  instructions  of  the 
manufacturer.  To  detect  insulin,  slides  were  incubated in  a  guinea-pig-
antiserum against pig insulin (Dako, Code A0564, 1:400) for 30 minutes. 
Then,  LSAB  staining  was  done  according  to  the  manufacturer`s 
recommendations with 5-minute-washes in TBS between the incubations. 
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For  a  blue  nuclear  counterstaining,  specimens  were  incubated  in 
hematoxylin  (Dako,  Glostrup,  Denmark,  Code  S3301)  for  5  minutes 
followed  by  a  5-minute-incubation  in  tap  water.  Finally,  samples  went 
through a series of ascending alcohol concentrations (70%, 96%, 100%) 
and  were  mounted  with  Entellan  (Merck,  Darmstadt,  Germany,  Code 
1.07961.0/00). Under omission of the primary antibodies, no staining could 
be observed. Tonsil, known to strongly express Ki67 at the protein level 
{e.g. \Troncone, 2005 #795;Korbonits, 2002 #802} was used as a positive 
control.
3.2.3   BETA CELL APOPTOSIS 
To investigate the turnover of beta-cells, pancreatic tissue sections 
were stained simultaneously for DNA strand breaks and insulin as follows: 
Antigen retrieval  was performed in pH 6 citrate  buffer  (Dako,  Glostrup, 
Denmark  Code  S  2369)  for  30  minutes.  Then,  TUNEL  staining  was 
performed by using the in situ cell death detection kit from Roche (Roche, 
Code 11 684 795 910), according to the manufacturer's recommendations. 
Prior  to  the  immunostaining  for  insulin,  samples  were  blocked  for 
unspecific  binding  of  the  antibodies  with  TBS containing  3% BSA and 
0,2% Triton X100 for 15 minutes. For the detection of insulin, the guinea-
pig-derived antiserum against pig insulin described above was applied for 
30  min  at  a  dilution  of  1:100 followed  by  the  incubation  in  Cy3 (red)-
labelled  secondary  antibody  developed  in  goat  (Jackson  Immuno 
Research, Code 106-165-603) that was applied in a dilution of 1:800 for 
15  minutes.  All  antibodies  were  diluted  in  Antibody  Diluent  from Dako 
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(Glostrup, Denmark, Code S0809). Finally,  the nuclei  were stained with 
DAPI  (blue)  by  incubation  in  a  0,33  µg/ml  DAPI  (Invitrogen,  Paisley, 
UK,Code SKU#1306]) solution in PBS for 5 minutes. Following 5-minute-
incubations  in  3  changes  of  distilled  water,  the  tissue  sections  were 
mounted with Dako Fluorescence Mounting Medium (Glostrup, Denmark, 
Code  S-3023)  and  stored  at  4-8°C in  the  dark.  Positive  and  negative 
controls  were  run  with  each  batch  of  samples.  DNAse-treated  tissue 
served as a positive control for the TUNEL reaction. As a negative control, 
primary antibodies and terminal transferase were omitted.
3.3 Morphometric analysis
For all morphometric analysis, pancreatic tissue specimens stained 
immunohistochemically as above described were used. All measurements 
were  performed  by  applying  specific  tools  of  the  software  Axiovision 
(version  4.5)  (Zeiss,  Oberkochen,  Germany)  to  images  of  the  tissue 
samples  that  were  generated  by  an  Axioplan  2-microscope  (Zeiss, 
Oberkochen, Germany) at appropriate magnifications. 
3.3.1 Fractional beta-cell area
The fractional beta-cell area of the control tissue sections and the 
healthy  parts  of  the  resected  tissue  from  insulinoma  patients  was 
determined by imaging the entire pancreatic section using the Axioplan 
microscope equipped with a motorized-stage,  at  100-fold  magnification. 
The Mosaix tool of the software Axiovision was used to create a tile image. 
The pancreatic tissue was surrounded using the contour 'measurement' 
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tool of the software, excluding artefacts or other different kind of tissues, 
possibly present in the section, from the analysis. Then, we measured  the 
red  areas  corresponding  to  the  insulin-positive  areas  in  the  selected 
pancreatic tissue using the colour detection 'measurement' tool. We used 
the same tool also to measure the red and not red areas in the tissue 
corresponding to the entire pancreatic area. Then, the beta cell area was 
expressed as percentage of insulin-positive area to the entire pancreatic 
area.
3.3.2  Islet size
For the determination of islet size, at least 20 representative islets 
in the healthy part of the resected tissue were imaged in the insulinoma 
cases and control subjects, each at 20x magnification, using the Axioplan 
microscope.  Only  islets  containing  a  minimum  of  5  beta-cells  were 
selected.  The  size  of  each  islet,  expressed  as  insular  area,  was 
determined  individually  using  the  contour  “measurement”  tool  of  the 
software Axiovision (Zeiss, Oberkochen, Germany). 
3.3.3 Beta cell nuclear diameter   
To asses the nuclear diameter of beta-cells, 5 randomly selected 
islets  per  section  were  photographed  at  40x  magnification  using  the 
Axioplan microscope. Five representative beta cell  nuclei  per islet were 
chosen if  they  had clear  and definable  nuclear  boundaries  within  beta 
cells,  circular  shape  and  appeared  as  they  were  cut  through  their 
maximum  diameter.  Then,  the  nuclei  were  encircled  by  the  contour 
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“measurement”  tool  of  the  software  Axiovision  and  their  area  was 
expressed (Zeiss, Oberkochen, Germany). The respective diameter was 
then calculated from the area displayed. 
3.3.4 Beta cell neogenesis
To examine the possible formation of  new beta-cells  from ductal 
progenitor  cells,  the  percentage  of  insulin-positive  duct  cells  was 
determined, as described (28). For these purposes, 10 randomly chosen 
visual fields containing pancreatic ducts were imaged at 20x magnification 
using the Axioplan microscope. Duct-cells were manually counted and the 
number of insulin-positive duct-cells per field was expressed in relation to 
the total number of duct cells.
3.3.5 Beta-cell replication
To determine the frequency of beta-cell replication, 10 random islets 
per  slide  stained  for  insulin  and  Ki67  were  imaged  at  20x  objective 
magnification  using  the  Axioplan  microscope.  The  number  of  cells  co-
stained  for  insulin  and  Ki67  was  counted  manually  and  expressed  in 
relation to the total number of insulin-positive cells.
3.3.6 Beta-cell apoptosis 
To determine the frequency of beta-cell apoptosis, 10 random islets 
per  slide  stained for  insulin  and TUNEL were imaged at  20x  objective 
magnification  using  the  Axioplan  microscope.  The  number  of  cells  co-
stained for insulin and TUNEL was counted manually and expressed in 
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relation to the total number of insulin-positive cells.
3.4 Statistical analysis
Subject  characteristics  are reported  as means ±  SD, results  are 
presented as means ± SEM. Statistical calculations were carried out by 
one-way ANOVA and Student’s t-test using Prism4 (Graph Pad software 




The  presence  of  insulinoma  tissue  was  confirmed  by  careful 
examination  of  the  tissue  sections  by  a  trained  pathologist  following 
specific  insulin  staining  in  all  cases.  A morphological  evaluation  of  the 
tumor-adjacent pancreatic tissue did not reveal any major abnormalities in 
the insulinoma patients. Thus, islets of regular shape and number could be 
detected in the unaffected tissue in all cases. Examples of tissue-scans 
showing  an insulin-producing  tumor  and  healthy  tissue  from a  control-
tissue are given in Figures 19 a and b1 and b2, respectively.
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1
Figure 19: Representative tissue sections from two insulinoma patients (female, 
age 62 (a1); female, age 56 (a2)) and a control pancreas (female, age 69; B). 
The large insulin-producing tumor in  panel (A) is evident  in  the centre of  the 
section. The pancreatic sections were immunohistochemically stained for insulin 
and imaged by scanning the entire tissue section at 100x magnification. The final 




4  .2 Quantitative morphometry  
Fractional  beta-cell  area  was  1.11%  ±  0.30%  in  the  tumor-free 
pancreatic tissue of the insulinoma patients and 0.78% ± 0.08% in the 
control group (p = 0,19) (Figure 20). 
There also were no differences in either mean islet size (6121.9 ± 
506.3 µm2 vs. 6879.8 ± 992.8 µm2, respectively, p = 0.62) (Figure 21) or 
the nuclear diameter of the beta-cells (6.48 ± 0.30 µm vs. 6.87 ± 0.15 µm, 
respectively,  p  =  0.20)  (Figure  22)  between  both  groups.  Thus,  the 
morphometric analysis of the tissue samples did not reveal any evidence 
of either beta-cell hypertrophy or beta-cell hyperplasia. 
Figure 20: Fractional beta-cell  area in the tumor-free pancreatic tissue of five 
insulinoma cases and ten control subjects. Results are presented  as means ± 
SEM. Statistics were carried-out using Students’ t-test.
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Figure 21: Islet size in the tumor-free pancreatic tissue of insulinoma cases and 
control subjects. Results are presented as means ± SEM. Statistics were carried-
out using Students’ t-test.
Figure 22:  Nuclear diameter of beta cells in the tumor-free pancreatic tissue of 
insulinoma cases and control subjects. Results are presented as means ± SEM. 
Statistics were carried-out using Students’ t-test.
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4.3 Beta cell turnover
Beta-cell replication, as determined by specific Ki67 labelling, was 
observed infrequently in both the insulinoma patients and controls (0% vs 
0.03%  ±  0.02%,  respectively)  (Figure  23).  There  were  no  obvious 
differences in the frequency of beta-cell replication between the groups, 
although the overall number of replicating cells was too low to calculate a 
meaningful  percentage.  However,  beta-cell  replication  was  abundantly 
detected in the actual tumor tissue, thereby affirming the validity of the 
staining. 
In  order  to  estimate  the  potential  contribution  of  ductal  islet 
neogenesis,  the  percentage  of  ductal  cells  expressing  insulin  was 
quantified as well. However, there were also no significant differences in 
this surrogate parameter (0.41% ± 0.26% vs. 0.24% ± 0.10%, respectively; 
p = 0.47) (Figure 24). 
Beta-cell apoptosis was determined by means of TUNEL labelling. 
There was a very low number of apoptotic beta-cells in both groups, with 
no  detectable  differences in  the  frequency of  TUNEL staining  between 
insulinoma patients and controls  (0.04% ± 0.02% vs 0%). Examples of 
TUNEL-positive beta-cells and exocrine tissue are given in figure 25a and 
b, respectively.
When  the  four  control  subjects  with  increased  fasting  glucose 
concentrations  were  excluded  from the  analyses,  the  results  remained 
similar,  with  no  significant  difference  in  any  of  the  parameters  being 
detectable between insulinoma patients and controls.
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Figure 23: Representative tissue section from an insulinoma patient (female, age 
62)  stained for Ki67 (brown) and insulin (red). A number of Ki67-positive beta-
cells  is  found  within  the  tumour  (upper  left),  whereas  replication  occurs  only 





Figure 24: Frequency of insulin-positive duct cells in five insulinoma cases and 
ten control  subjects.  Results are presented as means ± SEM. Statistics were 
carried-out using Students’ t-test (a). Representative picture of an insulin-positive 
pancreatic  duct  cell  in  an  insulinoma case  (male,  age  51)  (b)  and  a  control 
subject (female, age 58) (c). The section was immunohistochemically stained for 
insulin and imaged at 200-fold magnification. 
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c
 Figure  25:  Representative  figures  showing  a  TUNEL-positive  beta-cell  in  an 
insulinoma case (A; female, age 56) and in the exocrine pancreatic tissue of a 
control patient (B; female, age 69 years). The sections were stained for TUNEL 
(green) and insulin (red). The pictures were taken at 400x magnification.
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5. DISCUSSION (I)
The  present  study  was  undertaken  to  examine,  whether  the 
unregulated  insulin  release  from  intra-pancreatic  insulinomas  would 
influence beta-cell mass and turnover in the surrounding pancreatic tissue. 
A detailed morphometric  analysis  of  human pancreatic specimens from 
five patients with intra-pancreatic insulinomas and ten control subjects did 
not reveal any differences in either beta-cell area, beta-cell replication and 
islet neogenesis, or beta-cell apoptosis between the groups. 
The  results  of  the  present  study  in  insulinoma  patients  are  at 
variance  with  a  previous  evaluation  of  human  pancreatic  tissue  from 
patients  with  intra-pancreatic  gastrinomas  (76).  Using  a  similar 
experimental  approach,  this  previous  study  had  revealed  a  marked 
increase  in  fractional  beta-cell  area  and  beta-cell  replication  in  the 
pancreatic tissue immediately adjacent to the tumors. These findings have 
lent  support  to  the  concept  of  an  induction  of  beta-cell  replication  by 
gastrin. 
There  has  been  a  long-standing  debate  as  to  the  potential 
preservation of beta-cell mass by insulin. Thus, in tissue culture studies 
high  concentrations  of  insulin  have  been  found  to  induce  beta  cell 
replication and reduce beta-cell apoptosis (77), and experiments in beta-
cell  specific  insulin  receptor  knock-out  (βIRKO)  mice  have  revealed  a 
significant reduction in beta-cell mass and age-dependent manifestation of 
diabetes in the affected animals, thereby supporting a role for endogenous 
insulin  in  the  growth  and  maintenance  of  beta  cell  mass  (129,  130). 
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Furthermore,  clinical  studies  directly  comparing  endogenous  insulin 
secretion after two years of glucose-lowering therapy with either pre-mixed 
insulin or glibenclamide have shown a significant preservation of beta-cell 
function  by  the  insulin  therapy  approach  (79).  In  a  similar  way,  early 
initiation of insulin therapy in patients with newly-onset type 2 diabetes has 
led  to  a  marked  preservation  of  beta-cell  function  (80),  a  finding 
reminiscent  of  the  “honeymoon period”  often  observed in  patients  with 
type 1 diabetes after the initiation of insulin therapy (131). 
This  potential  preservation  of  beta-cell  function  by  insulin  could 
theoretically  be  mediated  by  two  different  mechanisms:  Thus,  a  direct 
effect of insulin on beta-cell survival has been suggested in a recent series 
of elegant studies (77). These experiments have pointed towards an Akt-
independent pathway, potentially involving the protein bridge-1, a Pdx1-
binding partner and regulator of beta-cell survival. The second mechanism 
by which exogenous insulin could potentially reduce the extent of beta-cell 
apoptosis  involves  the  mechanism  of  beta-cell  rest.  According  to  this 
concept, a chronically increased insulin secretory demand, induced by e.g. 
Hyperglycaemia,  insulin  resistance  of  beta-cell  deficiency,  leads  to  an 
over-stimulation of insulin secretion, which subsequently drives the beta-
cells to increased insulin biosynthesis (132). The chronic up-regulation of 
insulin biosynthesis may then lead to protein misfolding, the induction of 
endoplasmatic  reticulum (ER)  stress,  and ultimately  beta-cell  apoptosis 
(133-135).  According  to  such  reasoning,  exogenous  insulin  treatment 
might lower the secretory demand on the beta-cells,  thereby potentially 
protecting the cells from undergoing apoptosis (136, 137). 
 67
However,  while  local  over-production  of  insulin  from  insulioma 
tissue  may  on  the  one  hand  protect  beta-cells  from  apoptosis,  an 
alternative  scenario  is  also  conceivable:  Thus,  it  is  a  well-known 
phenomenon  from  other  endocrine  organs  that  local  hyperplasia  and 
excessive hormone secretion can lead to a compensatory regression of 
the  non-affected cells.  Such mechanism characterises  for  example  the 
regulation  of  cortisol  secretion  from  the  contralateral  adrenal  gland  in 
cases  of  unilateral  adrenal  adenomas (138,  139).  Assuming,  that  such 
compensatory  mechanism exists  in  the  islets  as  well,  one  might  even 
expect a reduction in beta-cell area as well as an increase rate of beta cell 
apoptosis in the tumor-free pancreas from insulinoma patients. 
In the present experiments, neither pancreatic beta-cell  area, nor 
beta-cell  replication  and  islet  neogenesis,  nor  beta-cell  apoptosis  were 
different  between  the  tumor-free  tissue  from  insulinoma  patients  and 
control subjects. While this may suggest that the effects of insulin on beta-
cell  proliferation in adult  humans in vivo are less pronounced that  one 
might have expected from rodent studies, it is also well possible that the 
protective  effects  of  the  locally  elevated  insulin  concentrations  were 
completely outbalanced by a compensatory regression of the insulinoma-
free pancreatic tissue. 
Some  limitations  need  to  be  born  in  mind  with  respect  to  the 
present  results:  first,  the  control  group was comprised of  patients  with 
benign pancreatic adenomas and extrapancreatic tumors. This was done 
by necessity,  because patients without any pancreatic diseases are not 
readily  subjected to pancreatic  surgery.  However,  in the present cases, 
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any obvious alterations of the pancreatic tissue were excluded by a careful 
pathological examination of the tissue. 
Secondly,  the  overall  frequencies  of  beta-cell  replication  and 
apoptosis were relatively small, thereby not allowing for formal statistical 
comparisons. Therefore, it is still possible that minor differences in islet cell 
turnover were overlooked because of the small numbers. Along the same 
line,  it  is  conceivable  that  significant  differences  between  insulinoma 
patients and control subjects would become detectable if a larger number 
of  cases  were  examined.  However,  in  previous  studies  about  the 
regulation  of  beta-cell  area and turnover  in  humans,  the differences in 
beta-cell replication between the groups were often several-fold (76, 140, 
141),  suggesting  that  if  present  at  all,  any  difference  between  the 
insulinoma patients and control subjects would be minor at best. 
While  the  present  results  therefore  need  to  be  interpreted  with 
some caution, it should be noted that any direct attempt to examine beta-
cell mass and turnover after exogenous insulin treatment is clearly limited 
by the obvious in-availability of human pancreatic specimens from healthy 
human  subjects  for  study  purposes.  Also,  examining  the  pancreas  of 
surgical  patients  receiving  pre-operative  insulin  treatment  for  clinical 
reasons bears the unavoidable risk of a strong selection bias, because 
insulin  treatment  is  typically  prescribed  at  more  advanced  stages  of 
diabetes. Therefore, even though the present findings need to be carefully 
interpreted,  they  may  be of  some clinical  relevance  in  order  to  judge, 
whether raising circulating insulin levels preserves of beta-cell mass and 
turnover in living humans. 
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Although the present study did not reveal any evidence of beta-cell 
protection by endogenous hyperinsulinaemia in the pancreas of patients 
without diabetes, this may well be different in a group of diabetic patients 
with overt hyperglycaemia. In fact, chronic hyperglycaemia has long been 
recognised as a key factor leading to the induction of beta-cell apoptosis 
(142, 143). It is therefore possible, that the local release of insulin from 
intra-pancreatic insulinomas has a much greater effect on beta-cell mass 
and  turnover  in  patients  with  overt  diabetes.  However,  because  the 
coincidence  of  type  2  diabetes  and  insulinoma  is  quite  rare,  such 
pancreatic  specimens  were  unfortunately  not  available  for  the  present 
analyses.
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6. MATERIALS AND METHODS (II)
6.1 Pancreatic tissue samples
6.1.1   Patients with type 2 diabetes 
Human pancreatic tissue was obtained at surgery from 7 patients 
(Table 3). Of these patients, 4 underwent surgery for the removal of benign 
pancreatic adenomas, 1 for the removal of intraductal papillary mucinous 
tumor, 2 underwent pancreatectomy because of tumors of the ampulla or 
papilla of Vater. All the patients had a history of known diabetes and were 
taking antidiabetic medications (Table 4).
6.1.2    Patients with diabetes secondary to pancreatic disease 
Human pancreatic tissue was obtained at surgery from 10 patients 
(Table 3), who underwent pancreatic resections. Of these patients, 7 had 
been diagnosed with chronic pancreatitis and 3 with pancreatic carcinoma. 
In all cases, the clinical diagnosis was confirmed by a trained pathologist. 
All  the  patients  had  a  history  of  known  diabetes  and  were  under 
antidiabetic treatment (Table 4).  
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6.1.3 Control subjects
11 non diabetic patients were chosen as controls (Table 2) as they 
underwent surgery for the removal of tumours not influencing the beta cell 
mass and function: 7 had benign pancreatic adenomas, 2 had intraductal 
papillary mucinous tumor and 2 had tumors of the ampulla of Vater and of 
the ductus choledochus, respectively.  Significant alterations of the overall 
pancreatic integrity were excluded by careful histological examination and 
none of the control subjects had a history of diabetes. 










SEX (F+M) 8+3 4+3 6+4
AGE (years) 59 ± 14.5 68.6 ± 8.1 63 ± 11.7
FASTING BLOOD 
GLUCOSE (  mg/dl) 
97.55 ± 12.4 128.3 ± 45.8 147.5 ± 19.3
HbA1c (%) 5.62 ± 0.33 7.5 ± 1.14 7.7 ± 1.17
Data are means ± SD.
Table 4. Patients subdivision according to antidiabetic treatment.
              Patients with type 2 diabetes                Patients with diabetes         
                                                              secondary to pancreatic disease
                 
                Insulin                       Oral               Insulin         Oral       Diet      None
N  UMBER      4        3                    6                   1            2            1
SEX   (F+M)  2+2                          2+1                3+3              0+1        2+0        1+0
AGE         71.8±3.5                 64.3±11.5       58±10.7             62      79±1.4       62
Data are means ± SD.
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6.2 Fluorescence and immunohistochemical tissue staining
Pancreatic  tissue  was  fixed  in  formaldehyde  and  embedded  in 
paraffin. Sequential 5 µm sections were stained as follows:
6.2.1 Fractional beta cell area
To  assess  the  fractional  beta-cell  area,  all  tissue  sections  were 
immunohistochemically  stained  for  insulin  and  DNA  as  follows:  After 
heating at 37°C over night or at 58°C for 30 minutes, pancreatic tissue 
sections  were  deparaffinized  in  two  subsequent  10-minutes  xylene-
incubations  and  subsequently  hydrated  through  graded  alcohol-series 
(100%,  95%,  70%,  water).  Antigen  retrieval  was  performed  in  Dako 
Cytomation  Target  Retrieval  Solution  pH  6  (Dako,  Glostrup,  Denmark, 
Code S2369) by heating for 30 minutes. After cooling of the samples to 
room  temperature  and  a  brief  rinse  in  distilled  water,  sections  were 
subsequently blocked for unspecific protein binding with TBS containing 
3% BSA and 0,2% Triton X100 for 10 minutes, for endogenous alkaline 
phosphatase causing unspecific staining by use of Levamisole from the 
Dako-Envision Dual Link System (Dako, Glostrup, Denmark, Code K4065) 
and for endogenous biotin by use of the Dako Cytomation Biotin Blocking 
System  (Dako,  Glostrup,  Denmark,  Code  X0590).  Then,  a  guinea  pig 
antiserum against pig insulin was applied for 30 minutes at a dilution of 
1:400 (Dako, Glostrup, Denmark, Code A0564). Subsequently, insulin was 
stained red by the use of the Dako-LSAB Real Detection System (Dako, 
Glostrup,  Denmark,  Code  K5005)  according  to  the  manufacturer`s 
recommendations with 5-minutes TBS-washes between the incubations. 
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For  a  blue  nuclear  counterstaining,  specimens  were  incubated  in 
hematoxylin  (Dako,  Glostrup,  Denmark,  Code  S3301)  for  5  minutes 
followed  by  a  5-minutes  tap  water-incubation.  Finally,  samples  went 
through a series of ascending alcohol concentrations (70%, 96%, 100%) 
and 5-minutes xylene-incubation and were mounted with Entellan (Merck, 
Darmstadt, Germany, Code 1.07961.0/00). Under omission of the primary 
antibodies, no staining could be observed.
6.2.2 Beta cell apoptosis and islet amyloid
To investigate the beta-cell apoptosis and the amount of amyloid in 
the islets, pancreatic tissue sections were stained simultaneously for DNA 
strand  breaks,  insulin,  amyloid  and  DNA as  follows:  Pancreatic  tissue 
sections went through heating and deparaffinizing procedures as above 
described.  Antigen  retrieval  was  performed  in  Dako  Cytomation  Target 
Retrieval Solution pH6 (Dako, Glostrup, Denmark, Code S 2369) for 30 
minutes.  For  the  detection  of  islet  amyloid  deposits,  the  sections  were 
stained with Thioflavin S (Sigma, St Louis, USA, Code T1892-25G) for 8 
minutes at room temperature. Then, TUNEL staining was performed by 
using the in situ cell death detection kit from Roche (Roche, Mannheim, 
Germany, Code 12 156 792 910), according to the recommendations of 
the manufacturer. Prior to the immunostaining for insulin, samples were 
blocked for unspecific binding of the antibodies with TBS containing 3% 
BSA and 0,2% Triton X100 for 15 minutes. For the detection of insulin, a 
guinea pig anti-insulin antibody was applied for 30 minutes in a dilution of 
1:400  followed  by  the  incubation  in  Dylight  649-labelled  secondary 
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antibody  developed  in  goat  (Jackson  Immuno  Research,  W.  Baltimore 
Pike, USA, Code 706 495 148) that was applied in a dilution of 1:100 for 
30  minutes.  All  antibodies  were  diluted  in  Antibody  Diluent  with 
Background  Reducing  Components  (Dako,  Glostrup,  Denmark,  Code 
S3022). Finally, the nuclei were stained with DAPI by incubation in a 0,33 
µg/ml DAPI (Invitrogen, Paisley, UK,Code SKU#1306) solution in PBS for 
5 minutes. Following 5-minute-incubations in 3 changes of distilled water, 
the  tissue  sections  were  mounted  with  Dako  Fluorescence  Mounting 
Medium (Dako, Glostrup, Denmark, Code S3023) and stored at 4-8°C in 
the  dark.  Positive  and  negative  controls  were  run  with  each  batch  of 
samples. DNAse-treated and kidney tissues served as a positive control 
for the TUNEL reaction and the Thioflavin S staining, respectively. As a 




For all morphometric analysis, pancreatic tissue specimens stained 
immunohistochemically as above described were used. All measurements 
were  performed  by  applying  specific  tools  of  the  software  Axiovision 
(version  4.5)  (Zeiss,  Oberkochen,  Germany)  to  images  of  the  tissue 
samples  that  were  generated  by  an  Axioplan  2-microscope  (Zeiss, 
Oberkochen, Germany) at appropriate magnifications. 
6.3.1 Fractional beta-cell area
The fractional beta-cell area of all tissue sections was determined 
by imaging the entire pancreatic section using the Axioplan microscope 
equipped with a motorized-stage, at 100-fold magnification. The Mosaix 
tool  of  the  software  Axiovision  was  used  to  create  a  tile  image.  The 
pancreatic tissue was surrounded using the contour 'measurement' tool of 
the software, excluding artefacts or other different kind of tissues, possibly 
present  in the section, from the analysis.  Then, we measured  the red 
areas  corresponding  to  the  insulin-positive  areas  in  the  selected 
pancreatic tissue using the colour detection 'measurement' tool. We used 
the same tool also to measure the red and not red areas in the tissue 
corresponding to the entire pancreatic area. Then, the beta cell area was 
expressed as percentage of insulin-positive area to the entire pancreatic 
area.
6.3.2 Beta-cell apoptosis
To determine the frequency of beta-cell apoptosis, 20 random islets 
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per slide stained for insulin, TUNEL, amyloid and DAPI were imaged at 
200-fold magnification using the Axioplan microscope. The number of cells 
co-stained for insulin and TUNEL was counted manually and expressed in 
relation to the total number of insulin-positive cells.
6.3.3 Islet amyloid
To determine the islet amyloid, 20 random islets per slide stained 
for  insulin,  TUNEL,  amyloid  and  DAPI  were  imaged  at  200-fold 
magnification using the Axioplan microscope. The islets were scored for 
the extent of islet amyloid using a scale from 0 to 5, where 0 indicated that 
there were no amyloid deposits in the islets, 1 indicated the presence of 
small amyloid deposits (mainly spherical puncta and curvilinear structure) 
in the islets, 2 indicated the presence of bigger amyloid deposits (spherical 
puncta  and  larger  curvilinear  structures)  in  the  islets,  3  indicated  the 
presence of aggregates of amyloid fibrils of small  extent in the islets, 4 
indicated the presence of aggregates of amyloid fibrils of mid extent in the 
islets,  5 indicated the presence of aggregates of amyloid fibrils  of wide 
extent  in  the  islets.  In  the  case  of  islets  with  score  4  and  5,  the 
“measurement”  tool  of  the  software  Axiovision  (Zeiss,  Oberkochen, 
Germany) was used to measure the amyloid positive area in the islet and 
the total insular area. The amyloid quantity in the islet was expressed as 
percentage of amyloid positive area to the total islet area. Examples of 
scores for islet amyloid are given in figures 26, 27, 28, 29 and 30.  
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6.4 Statistical analysis
Subject  characteristics  are reported  as means ±  SD, results  are 
presented as means ± SEM. Statistical calculations were carried out by 
one-way ANOVA using Prism4 (Graph Pad software Inc.,  La Jolla,  CA, 
USA).     
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Figure  26:  An  example  of  an  islet  with  score  1.  Staining  for  amyloid  with 
Thioflavin S (green) and insulin (cyan) (a). Staining for amyloid with Thioflavin S 




Figure  27:  An  example  of  an  islet  with  score  2.  Staining  for  amyloid  with 
Thioflavin S (green) and insulin (cyan) (a). Staining for amyloid with Thioflavin S 




Figure  28:  An  example  of  an  islet  with  score  3.  Staining  for  amyloid  with 
Thioflavin S (green) and insulin (cyan) (a). Staining for amyloid with Thioflavin S 




Figure  29:  An  example  of  an  islet  with  score  4.  Staining  for  amyloid  with 
Thioflavin S (green) and insulin (cyan) (a). Staining for amyloid with Thioflavin S 




Figure  30:  An  example  of  an  islet  with  score  5.  Staining  for  amyloid  with 
Thioflavin S (green) and insulin (cyan) (a). Staining for amyloid with Thioflavin S 







There  was  a  significant  difference  in  fractional  beta-cell  area 
between  all  three  groups.  Fractional  beta-cell  area  was  higher  in  the 
control  subjects than in  patients with type 2 diabetes  and  patients with 
diabetes secondary to pancreatic disease.  Fractional beta-cell  area was 
lower in  patients with diabetes secondary to pancreatic disease  than in 
patients with type 2 diabetes (0.76% ± 0.13%, 0.57% ± 0.09% and 0.33% 
±  0.07%,  respectively,  p=0.021)  (Figure  31).  Examples  of  Islets  of 
Langerhans in the three groups are given in Figure 32 a, b and c.
Figure 31: Fractional beta-cell area in patients with type 2 diabetes, patients with 
with  diabetes  secondary  to  pancreatic  disease  and  patients  without  diabetes 
(controls).  Results are presented as means ± SEM. Statistics were carried-out 





Figure  32:  Representative  tissue  sections  from  a)  control  subject  without 
diabetes (a; female, age 69), b) patient with type 2 diabetes (b; male, age 68) 
and c) patient with pancreatic carcinoma and type 2 diabetes (c; female, age 78). 
The  pancreatic  sections  were  immunohistochemically  stained  for  insulin  and 
imaged at 200-fold magnification.
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4  .2 Beta-cell apoptosis  
The overall frequency of apoptosis was relatively small, thereby not 
allowing for  formal  statistical  comparisons.  Anyway,  beta cell  apoptosis 
was  observed  more  frequently  in  patients  with  diabetes  secondary  to 
pancreatic  diseases. Beta-cell  apoptosis  was  0.07  % ±  0.07  % in  the 
control group, 0.05 % ± 0.05 % in patients with type 2 diabetes and 0.58 
%  ± 0.29 % in  patients with diabetes secondary to pancreatic diseases 
(p=0.10) (Figure 33). Examples of TUNEL-positive beta cells and TUNEL-
negative beta cells are given in Figure 34 a, b and c.
Figure  33:  Frequency  of TUNEL positive  beta  cells  in  patients  with  type  2 
diabetes (cases 1), patients with chronic pancreatitis or pancreatic carcinoma and 
type 2 diabetes (cases 2) and patients without diabetes (controls).  Results are 





Figure 34:  Representative tissue sections from a) control without diabetes (a; 
female, age 66), b) patient with type 2 diabetes (b; female, age 70) and c) patient 
with  pancreatic  carcinoma  and  type  2  diabetes  (c;  female,  age  80).  The 
pancreatic sections were stained for amyloid with Thioflavin S (green),  insulin 
(cyan), cell apoptosis with TUNEL (red) and nuclei with DAPI (blue). The pictures 




Islet amyloid was present in small amounts in most of the islets of 
all subjects in the three groups. There were no significant differences in 
the  extent  of  islet  amyloid  between the groups.  Only  in one patient  of 
patients with type 2 diabetes we observed big aggregates of amyloid fibrils 
in the majority of the islets. The extent of the islet amyloid was 0.99% ± 
0.05% in the control group, 1.44% ± 0.33% in patients with type 2 diabetes 
and  1.04%  ±  0.08% in  patients  with  diabetes  secondary  to  pancreatic 
disease (p=0.13) (Figure 35). Islet amyloid area was 0.35% ± 0.27% in the 
control group, 2.71% ± 2.35% in patients with type 2 diabetes and 0.27% ± 
0.27% in patients with diabetes secondary to pancreatic disease (p=0.24) 
(Figure 36). Examples of amyloid deposits in the control group, in patients 
with diabetes secondary to pancreatic disease and in patients with type 2 
diabetes are given in Figure 37 a and b, Figure 38 a and b and figure 39 a 
and b, respectively.
 90
Figure 35:  Extent of  islet  amyloid in patients with type 2 diabetes (cases 1),  
patients with chronic pancreatitis or pancreatic carcinoma and type 2 diabetes 
(cases  2)  and  patients  without  diabetes  (controls).  Results  are  presented  as 
means ± SEM. Statistics were carried-out using one-way ANOVA.
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Figure 36:  Percentage of amyloid positive area in islets of patients with type 2 
diabetes (cases 1), patients with chronic pancreatitis or pancreatic carcinoma and 
type 2 diabetes (cases 2) and patients without diabetes (controls). Results are 
presented as means ± SEM. Statistics were carried-out using one-way ANOVA.
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Figure  37:  Pancreatic  islet  amyloid  in  a  66-year-old  female  without  diabetes 
(control).  The  pancreatic  sections  were  stained  for  amyloid  with  Thioflavin  S 
(green),   insulin  (cyan)  and  nuclei  with  DAPI  (blue).  Small  amyloid  deposits, 
mainly  spherical puncta and curvilinear structure, were found in islets containing 




Figure 38: Pancreatic islet amyloid in a 80-year-old female with with pancreatic 
carcinoma and type 2 diabetes (case 2). The pancreatic sections were stained for 
amyloid with Thioflavin S (green),   insulin (cyan) and nuclei with DAPI (blue). 
Small amyloid deposits as spherical puncta were found in islets containing many 




Figure 39:  Pancreatic  islet  amyloid in  a  70-year-old  female  with  with  type 2 
diabetes  (case  1).  The  pancreatic  sections  were  stained  for  amyloid  with 
Thioflavin S (green), insulin (cyan) and nuclei with DAPI (blue). Big aggregates of 
amyloid were found to take place in a wide extension in islets containing some 





The present study was undertaken to examine the presence and 
quantity  of  amyloid aggregates and their  role  on beta cell  apoptosis in 
patients  with  type  2  diabetes  and  patients  with  diabetes  secondary  to 
pancreatic diseases comparing them with control subjects.
The morphometric analysis of human pancreatic specimens from 10 
patients with chronic pancreatitis or pancreatic carcinoma and secondary 
diabetes,  7  patients  with  type  2  diabetes  and  11  non  diabetic  control 
subjects revealed a significant difference in the fractional beta-cell  area 
between these 3 groups but no difference could be seen, instead, in the 
beta cell apoptosis and islet amyloid extent or area. The difference in the 
beta  cell  area  observed  between  groups  is  in  agreement  to  previous 
morphometric studies in patients with type 2 diabetes and patients with 
diabetes secondary to chronic pancreatitis. In patients with type 2 diabetes 
there is often a 40-60% reduction of beta cell mass (28, 44, 57),  due to an 
increased  beta  cell  apoptosis,  that  contributes  to  an  impaired  insulin 
secretion and a 30% reduction of beta cell mass has been shown, also, in 
subjects  with  chronic  pancreatitis  and  diabetes  compared  to  control 
subjects (144) without any difference in the beta cell turnover. 
In  our  study,  the  difference in  the  beta  cell  area  between the  3 
groups does not depend on an increase of beta cell apoptosis as there is 
no  difference  in  this  parameter  although  a  non  significant  trend  to  an 
increased cellular death is present in the patients with diabetes secondary 
to chronic pancreatitis or pancreatic carcinoma. 
What  decides  the  fate  of  a  beta  cell  is  the  result  of  a  mutual 
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influence between its  genetic  background  and the  external  stimuli  and 
environmental conditions. One of these stimuli, definitely important for the 
beta  cell,  is  represented by  the  plasma glycemic  levels  that,  normally, 
regulate the cell activity. It has been observed that an excessive quantity 
of  glucose  over  a  prolonged  period  has  negative  effects,  called 
glucotoxicity,  on  beta  cell  function  and  insulin  sensitivity.  Chronic 
hyperglycemia  causes  an  increased  basal  insulin  release,  a  reduced 
response  to  stimulus  to  secrete  insulin,  a  gradual  depletion  of  insulin 
stores, a reduced transcription of insulin gene and an increase of beta cell 
apoptosis (41, 145).  It seems that an high glucose metabolism take to an 
increase of apoptotic rate through an excessive mitochondrial production 
of  reactive  oxygen  species  (ROS)  as  oxidative  stress  markers,  like 
nitrotyrosine, are in high levels in diabetic islets. Interventions on oxidative 
stress,  like  addition  of  anti-oxidant  glutathione,  lower  the  nitrotyrosine 
levels and improve the beta cell  secretory function and increase insulin 
expression (41). Antioxidants administration increases also beta cell mass 
and decreases beta cell  apoptosis  rates in  an animal  model  of  type 2 
diabetes (146). Then, pharmacological treatments to lower and control the 
plasma glycemic levels  in type 2 diabetes can prevent  the progressive 
beta cell dysfunction and death, through a reduction of oxidative stress. In 
our study patients with type 2 diabetes and those with diabetes secondary 
to  chronic  pancreatitis  or  pancreatic  carcinoma  are  treated  with 
hypoglycemic  drugs  that  could  help  to  prevent  apoptosis  in  beta  cells 
whose functionality is not fully compromised and that have not started a 
death internal programme yet. 
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Besides glucotoxicity, there are also other factors that, potentially, 
can influence the beta cell survival, like amyloid deposits, formed by the 
deposition  of  IAPP  aggregates.  The  role  of  amyloid  in  the  beta  cell 
dysfunction is controversial  as some studies have found an association 
between amyloid fibrils and a reduced beta cell mass and apoptosis (147) 
while others have not been able to show any association between amyloid 
and type 2 diabetes duration (148).  In addition, some scientists believe 
that  small  oligomers  of  IAPP  and  not  big  fibrils  aggregates  are 
responsable for the beta cell death and experiments in vitro and in animal 
models  seem to  support  that  thesis  (119-121,  123).  Amyloid  oligomers 
have been shown also in the Langerhans islets of diabetic patients where 
apoptotic beta cells are also present (114). Anyway, this hypothesis needs 
to  be  proved  with  quantitative  studies  on  human islets  and  with  more 
specific methods. In our study we have seen amyloid deposits, mainly of 
small  size,  in  all  patients  of  the  3  groups  considered,  without  any 
significant  difference.  We  expected  to  find  a  higher  mean  of  amyloid 
deposition in the Langerhans islets of type 2 diabetes patients as reported 
in most of the literature. Anyway, Clark et al. found a mean value of 6.5% 
in islet amyloid area in diabetics (106) and lately Hai-Lu Zhao et al. have 
found patients with type 2 diabetes that do not show amyloid fibrils in their 
islets but rather a diffuse oligomer deposition that is present also in all non 
diabetic patients they considered for that study (114). Also, we detected in 
all our patients amyloid aggregates of a reduced size with an intracellular 
and extracellular localization. We used thioflavin S to stain the amyloid 
deposits,  a  fluorescent  dye  that,  like  its  analogue  thioflavin  t,  is  more 
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sensible in detecting amyloid fibrils than the traditional Congo Red staining 
(149, 150). It is possible to speculate that thioflavin s binds not only the 
amyloid fibrils but also small aggregates of IAPP monomers, oligomers, as 
seen in experiments with the analogue compound, thioflavin t (149).  The 
beta cells  in Langerhans islets  are highly  active in the biogenesis  and 
secretion of hormones and it is possible to think that, mainly, in the cellular 
compartments, ER, Golgi apparatus and secretory granules where these 
processes take place there is a temporary aggregation of IAPP due to its 
high concentration and its tendancy to assume in a part of its structure a 
beta sheet conformation fibril prone. This kind of aggregation and a further 
aggregation in a more complex structures, like fibrils, could be avoided by 
the cellular systems that assist the protein folding and by the interaction of 
IAPP with other molecules, like insulin (83).  Then, this could explain why 
we observed small amyloid aggregates in non diabetic patients. Amyloid 
deposition  was  also  present  in  all  patients  with  diabetes  secondary  to 
chronic  pancreatitis  or  pancreatic  carcinoma  and  then  caused  by  a 
different pathogenetic mechanism than that triggering type 2 diabetes. We 
did not report any difference in amyloid deposition and beta cell apoptosis 
between non diabetic subjects,  type 2 diabetic  patients  and those with 
diabetes  secondary  to  chronic  pancreatitis  and  pancreas  carcinoma, 
suggesting that amyloid deposition is not exclusively associated to type 2 
diabetes and could not be a cause of beta cell apoptosis in this disease. 
Anyway, our study shows some limitations: the number of patients 
in the 3 considered groups was not so high and, then, it is possible that 
differences in the beta cell apoptosis or islet amyloid extent or area could 
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have been, possibly, more pronounced with larger number of cases.
In addition, the control group was comprised of patients with benign 
pancreatic  adenomas  and  extrapancreatic  tumors  that  can  produce 
alterations  of  pancreatic  tissue.  This  was  done  by  necessity,  because 
human pancreatic biopsies from patients without any pancreatic diseases 
are  ethically  unacceptable.  However,  in  the  present  cases,  suspected 
pancreatic tissues were excluded.
We used thioflavin s staining to detect amyloid that can not be used 
to distinguish exactly between the species of amyloid deposits: different 
types of oligomers, protofibrils and fibrils.
 
 
       
 100
9. CONCLUSIONS
The research activity focused on two research project.
The aim of the first project was to evaluate the effects of high local 
insulin  levels  on beta  cell  turnover  in  vivo,  in  a  model  of  endogenous 
hyperinsulinism.  We could not find any differences in beta-cell area and 
turnover  between  the  tumor-free  pancreas  of  insulinoma  patients  and 
control subjects, suggesting that high endogenous insulin levels have no 
effects  on  beta  cells.  Future  in  vivo  studies,  ideally  employing  larger 
animal models, are warranted to further evaluate the impact of exogenous 
insulin on beta-cell turnover.
The  aim  of  the  second  project,  that  is  still  in  progress,  was  to 
examine the presence and quantity of amyloid deposits and their role on 
beta cell death in a condition of reduced insulin secretion because of faulty 
beta  cells  or  because  of  pancreatic  diseases.  We  found  a  significant 
difference in beta cell area but no differences in beta cell apoptosis and 
amyloid deposition between type 2 diabetic patients, patients with diabetes 
secondary  to  chronic  pancreatitis  or  pancreatic  carcinoma  and  non 
diabetic  control  subjects,  suggesting  that  amyloid  deposition  is  not  an 
exclusive phenomenon of type 2 diabetic islets and can not be a cause of 
beta  cell  death  in  this  disease.  Future  larger  studies,  involving  also 
appropriate animal models and sophisticated techniques, could be useful 
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